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1 INTRODUCTION 
As the number of cancer cases worldwide increases at an alarming rate, the effects 
are tremendously challenging to the public health systems and to the afflicted 
individual alike. The oncoviral research, conducted during the previous few decades, 
has determined that up to 20% of the cancer cases can be attributed to viral 
infections (105). In particular types of cancer, some viruses indisputably facilitate the 
initiation and the development of the disease. For instance, up to 80% of 
hepatocellular carcinomas (HCCs) are associated with the human hepatitis B virus 
(HBV) and human hepatitis C virus (HCV) while in almost all cases of cervical 
carcinomas the Human papillomavirus (HPV) has been identified as the disease 
catalyst (53). 
1.1 History of oncoviral research 
(Adapted, unless otherwise mentioned, from Cann (16) and Coffin (22)). 
1908: Vilhelm Ellerman and Oluf Bang first demonstrated that avian leukosis virus 
could be transmitted after cell-free filtration to new chickens, causing leukemia. 
1911: Peyton Rous reported cell free transmission of sarcoma in chicken and 
isolated the infectious agent Rous sarcoma virus (RSV) (134).  
1933: Richard Edwin Shope discovered cottontail rabbit papillomavirus or Shope 
papillomavirus, the first mammalian tumor virus. 
1936: John J. Bittner discovered mouse mammary tumor virus as an 
"extrachromosomal factor" (i.e., virus) transmitted among laboratory strains of mice 
by breast feeding (10). 
1951: Ludwig Gross observed vertical (germ line) transmission of cancers. 
1957: The Friend murine leukemia virus discovered by Charlotte Friend provided an 
animal model system for the study of erythropoiesis and the multistep nature of 
cancer. 
1960's: Temin and Baltimore simultaneously demonstrated that retrovirus particles 
contain a ribonucleic acid (RNA)-dependent desoxyribonucleic acid (DNA) 
polymerase-reverse transcriptase (Nobel prize awarded to Baltimore and Temin, 
1975).  
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1964: Anthony Epstein, Bert Achong and Yvonne Barr identified the first human 
cancer virus from Burkitt lymphoma cells. This virus is formally known as human 
herpesvirus 4 but more commonly called Epstein-Barr Virus or EBV (35). 
Mid-1960s: Baruch Blumberg first physically isolated and characterized Hepatitis B, 
co-receiving in 1976 Nobel Prize in Medicine or Physiology (Nobelprize.org).  
1969: Huebner and Todaro proposed the viral oncogene hypothesis - the 
transmission of viral and oncogenic information as genetic elements. This explained 
the vertical (germ line) transmission of 'cancers', first observed by Gross, 1951.  
1981: Gallo and co-workers discovered Human T-cell leukemia virus, which was the 
first pathogenic human retrovirus to be identified.  
1983: Barré-Sinoussi et al discovered Human immunodeficiency virus (HIV) - the 
causative agent of Acquired immunodeficiency syndrome (AIDS).  
1984–86: Harald zur Hausen, together with Lutz Gissman, discovered first HPV16 
and then HPV18, responsible for approximately 70% of cervical cancers. For the 
discovery that HPVs cause human cancer, zur Hausen won a Nobel Prize in 2008 
(Nobelprize.org). 
1994: Patrick S. Moore and Yuan Chang isolated Kaposi sarcoma-associated 
herpesvirus (KSHV). This search was driven by the work of V. Beral, T. Peterman 
and H. Jaffe who showed that this cancer must have another infectious cause 
besides HIV itself (9). Subsequent studies revealed that KSHV is responsible for the 
epidemiologic patterns of Kaposi’s sarcoma (KS) and related cancers (6). 
2008: A method developed by Chang and Moore (digital transcriptome subtraction) 
was used to isolate DNA fragments of Merkel cell polyomavirus from a Merkel cell 
carcinoma and it is now believed that this virus causes 70–80% of these cancers 
(37). This is the first polyomavirus to be well-established as the cause of a human 
cancer. 
1.2 Oncogenic viruses 
1.2.1 General aspects of viral oncogenesis 
The infectious nature of oncogenic viruses sets them apart from other carcinogenic 
agents. Therefore, the viral infection’s pathogenesis and the host response should 
both be extensively researched in order to acquire a thorough understanding of the 
resulting cancer. Most oncogenic viruses share some common features, although 
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they often belong to different virus families and use various strategies to contribute to 
cancer development. One such feature is their ability to infect, but not destroy, their 
host cell. In contrast to many disease-causing viruses, the oncogenic viruses tend to 
establish long-term persistent infections. As a result, they have developed advanced 
host immune response evasion strategies which would otherwise eradicate the virus. 
In spite of the viral etiology of several cancers, it seems the viruses may often 
contribute to, but are insufficient for, carcinogenesis; in fact, the majority of tumor 
virus-infected individuals do not develop cancer. Even for those patients that do 
develop cancer, several years can pass between the initial infection and the tumor 
progression. In addition, a variety of co-factors might also play a significant role in the 
oncogenesis. Examples of such factors include host immunity and chronic 
inflammation. In short, the long-term interactions between a virus and its host are 
essential features of the oncogenic viruses, as they initiate a variety of molecular 
events that may contribute to subsequent virus-mediated tumorogenesis (23). 
1.2.2 Classification of oncogenic viruses 
Oncogenic viruses are distributed into two major classes, viruses having DNA as a 
genome (DNA viruses) and those containing RNA as a genome (RNA viruses). Table 
1.1 lists the known oncogenic viruses.  
Table 1.1: Examples of human oncogenic viruses 
Family Disease Tumor Associated virus 
DNA viruses    
Papillomaviridae Warts, including 
sexual transmitted 
genital warts 
Cervical 
carcinoma 
Human 
papillomaviruses 
(multiple types) 
Herpesviridae  Kaposi's sarcoma Human 
herpesvirus-8 
 Infectious 
mononucleosis 
Burkitt's 
lymphoma 
Epstein–Barr virus 
Hepadnaviridae Infectious hepatitis Hepatocellular 
carcinoma 
Hepatitis B virus 
Poxviridae Smallpox Malignant-type 
smallpox 
Vaccinia virus 
Adenoviridae Upper respiratory Adenocarcinomas Human adenovirus 
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tract infection (cancer of 
glandular 
epithelial tissues) 
Polyomaviridae Progressive 
multifocal 
leukoencephalopathy 
and others 
Merkel cell 
carcinoma 
Human 
polyomaviruses 
RNA viruses    
Retroviridae  T cell leukaemia 
or lymphoma 
Human T cell 
leukaemia virus-1 
Flaviviridae Non-A, non-B 
hepatitis, hepatic 
steatosis 
Hepatocellular 
carcinoma 
Hepatitis C virus  
 
1.2.3 Mechanisms of oncogenesis 
Tumor-associated viruses often lead to malignancies with a prolonged latency and in 
conjunction with other environmental or host-related cooperating events, including 
nutritional status, environmental factors, parasitic or viral infection, chronic 
inflammation, and immunosuppression. The oncogenic mechanisms used by 
different viruses differ significantly. However, there are some common mechanisms 
that are used by viruses to induce cellular transformation. 
Table 1.2: Mechanisms of oncogenesis and related viruses 
Mechanisms Viruses 
Perturbation of signaling pathways EBV, KSHV, HPV 
Deregulation of cell cycle HPV, HTLV-1 
Escape of apoptosis EBV, HPV 
Immortalization of cells KSHV, HPV 
Induction of genetic instability HCV, HPV, HTLV-1 
Insertional mutagenesis HBV, HPV 
Induction of chronic inflammation HBV, HCV 
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EBV - Epstein-Barr Virus; HBV - human hepatitis B virus; HCV- human hepatitis C virus; 
HTLV - Human T-cell leukemia virus 1; HPV - Human papillomavirus; KSHV - Kaposi 
sarcoma-associated herpesvirus 
Perturbation of signaling pathways is comprised of a mimicking of the signaling 
ligands and the cellular signaling receptors as well as an activation of the cell surface 
receptors. These pseudo-signals are passed on, integrated, furcated and interpreted 
by intracellular signaling networks for cellular transformation (102, 128). 
Oncogenic viruses have developed multiple levels of regulation to promote cell cycle 
progression and cell proliferation, a mechanism referred to as deregulation of the 
cell cycle. At the heart of this process is a signal to the cell cycle’s regulatory system 
that leads to the unchecked entry of the cell into phase S (the phase, where the cell 
cycle proceeds autonomously, and independent of extracellular signals).  
The oncogenic viral infection imposes a significant amount of stress on cells that 
would induce apoptosis under normal conditions. To avoid premature cell death, 
these viruses apply several tactics to counteract apoptosis. The apoptosis escape 
comprises the inactivation of the tumor suppressor gene p53. This gene’s mutation 
occurs in more than 50% of all human cancers (51). For examples, HPV E6 (protein 
from an early region of HPV DNA-genome (157)) suppresses the normal functions of 
p53 through inhibition of p53 DNA-binding activity or by sequestering p53 in the 
cytoplasmic compartment (149). This suppression, carried out together with other 
mechanisms used by the virus, leads to the neoplastic processes in infected 
individuals. 
Immortalization of the cells is another method to promote tumor development. 
Normal mammalian cells have limited propagation potentials, averaging about 60-70 
cell divisions. This limited ability of cells is due to an autonomous cell generation 
counting device known as a telomere, which can be replenished by telomerase and 
therefore increase the number of cell divisions. Several oncogenic viruses target the 
telomerase to immortalize their infected cells. Through this way, the cancer cells 
obtain unlimited multiplication potentials (51).  
One of the main hallmarks of cancer cells is the intrinsic genetic instability resulting in 
gene mutations. The induction of genetic instability leads to the elevated 
mutability of cancer cells that provides them with a significantly higher chance of 
gathering enough mutations to reach the stage of malignant transformation (51). 
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The integration of proviral DNA into the host genome is an integral part of the 
retroviral life cycle. This integration may occur in the vicinity of or inside important 
cellular genes, leading to their mutations. This mechanism of tumor development is 
called insertional mutagenesis and will be addressed in further detail in the 
Retroviruses section. 
Chronic inflammation in response to viral infection can also lead to cancer 
development. For cancer development the inflammatory response sustains and 
provides the initiated tumor cells with an environment rich in growth/survival factors, 
activated stroma and DNA-damaging agents, which collectively promote cell 
proliferation as well as neoplastic transformation (24). 
1.3 Anti-tumor immune response 
McFarlane Burnet and Lewis Thomas introduced the tumor immunological 
surveillance theory in the 1950s (13, 14). It described how the host’s immune 
system recognizes newly arising tumors’ antigens and eliminates these tumors 
before they become clinically evident. Progressive cancer was understood as an 
infrequent event in which the tumor cell evaded the immune system’s effective 
control. Now it is reasonably clear that the immune system cannot entirely control 
tumor development or protect against its progression and metastasis. Nevertheless, 
the host immune system, including both innate and adaptive mechanisms, remains 
the main native protection in tumor control, especially with a clear etiological factor 
(viral). 
1.3.1 The tumor-draining lymph nodes 
The lymph nodes (LNs) are highly organized lymphoid organs composed of different 
types of immune cells. The latter are strategically positioned throughout the body and 
they play an essential role in any immune response. The tumor-draining lymph nodes 
(drLNs) lie immediately downstream of tumors where they undergo profound 
alterations due to the presence of the upstream tumor. They are currently emerging 
as an essential part of tumor immunology. Structurally, the drLNs form the site which 
tumor antigens first drain and tumor-derived DC initially migrate to. These cells 
display the antigen to recirculating T lymphocytes, which they also assist in 
activating. B cells, which encounter antigens as they migrate through the lymph 
node, are also arrested and activated with the help of some of the activated T cells. 
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The antigen-specific lymphocytes leave the lymph nodes as effector cells once they 
have undergone a period of proliferation and differentiation (67).  
The drLN is the physical location where cells of the naïve immune system first 
encounter the tumor antigens. This encounter is the moment of critical decision 
between initiation of activation and immune tolerance, when the immune system 
ignores, or fails to react to an antigen. Therefore, the local microenvironment in 
drLNs turns out to be a key factor in determining the course of the consequent anti-
tumor immune response (97). 
1.3.2 Innate immunity 
The innate immune system is the first intrinsically present line of defense against 
invading organisms. Innate immunity comprises various innate immune cells, 
including macrophages, dendritic cells (DCs), neutrophils and natural killer cells (NK) 
cells and various components of the complement system. In addition, the innate 
immune system has anatomical features functioning as barriers to infection. Pattern-
recognition receptors (PRRs), such as Toll-like receptors (TLRs), on the cell surface 
of macrophages and dendritic cells (DCs) recognize the conserved pathogen-derived 
molecules or the pathogen associated molecular patterns (PAMPs). Binding of 
PAMPs to TLRs leads to production of pro-inflammatory cytokines and chemokines. 
NK cells belong to the innate immune system as they are able to respond to 
pathogens immediately in a non-specific manner. NK cells are activated in response 
to interferons or macrophage-derived cytokines. They are also cytotoxic; small 
granules in their cytoplasm contain special proteins such as perforin and proteases 
known as granzymes. The release of these components leads to the induction of 
apoptosis in the target cells.  
Another important innate defense mechanism is the ingestion of extracellular 
particulate material by phagocytosis. Most phagocytosis is conducted by specialized 
cells, such as macrophages/monocytes, and granulocytes (especially neutrophils); 
which can engulf and kill pathogens in phagosomes. DCs can also contribute to the 
process of phagocytosis. Theirs main function is the recognition and degradation of 
the pathogens. Then, DCs present pathogen with the help of the major 
histocompatibility complex (MHC) molecules to naïve T cells and consequently 
launch the adaptive immune response (67).  
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Several observations suggest that innate immune cells play an important role in the 
host’s defense against tumors. For instance, in humans the Chediak-Higashi 
syndrome – an autosomal recessive disorder – is associated with impairment in 
neutrophils, macrophages, and NK cells, and an increased incidence of lymphomas 
(143).  
1.3.3 Adaptive immunity 
The term ‘adaptive’ refers to the differentiation of self from non-self and the adjusting 
of the response to the particular foreign pathogen. The adaptive immune response 
comprises B-lymphocytes that produce antibodies, often called the humoral response 
and T-lymphocytes that recognize and eventually kill infected or tumor cell, called the 
cell-mediated response. 
Adaptive immunity is triggered when a pathogen evades the innate immune system 
and generates a threshold level of antigen. The major functions of the adaptive 
immune system include: 
 The recognition of specific foreign antigens during the process of antigen 
presentation 
 The generation of responses that are tailored to maximally eliminate specific 
pathogen-infected or tumor cells 
 The development of immunological memory, where each pathogen is 
‘remembered’ by a signature antibody 
T cell maturation 
Progenitor T cells from the earlier sites of hematopoiesis begin to migrate from the 
bone marrow where they generated to the thymus. Thymus is the main source of all 
T cells. In thymus T cells diversify and then are shaped into an effective primary T 
cell repertoire by the selection processes. One of these, positive selection, permits 
the survival of only those T cells whose T cell receptors (TCRs) are capable of 
recognizing self-MHC molecules. It is thus responsible for the creation of a self-MHC-
restricted repertoire of T cells. The other, negative selection eliminates T cells that 
react too strongly with self-MHC or with self-MHC plus self-peptides. It is an 
extremely important factor in generating a primary T cell repertoire that is self-
tolerant. There are two main T cell subsets produced after being maturated in 
thymus: CD4+ and CD8+ T cells (43). 
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T cell activation and differentiation 
Recognition of the pathogens by DCs leads to their activation and maturation. Mature 
DCs have increased expression of MHC class I and class II. DCs are also known to 
express different types of T cell co-stimulatory molecules such as CD80 (B7.1), CD86 
(B7.2) and etc. on their surface. The receptor for B7 molecules on the T cells is 
CD28, a member of Ig superfamily like B7 molecules. Macrophages and B cells 
similarly become activated to express B7 molecules on their surface. DCs, 
macrophages and B cells are professional antigen-presenting cells even though DCs 
are much stronger antigen presenting cells (APCs) than macrophages and B cells. 
DCs migrate from the periphery through afferent lymphatic channels to draining 
lymph nodes (drLNs). Pathogen-activated DCs present these pathogen-derived 
antigens to T cells and stimulate the differentiation of naïve T cells into various 
subtypes to start the adaptive immune response. T cells express the TCR that can 
recognize tumor antigen on MHC molecules on tumor cells and APC (34, 135). There 
are two major subtypes of T cells based on the expression of two different 
coreceptors. T cells that co-express CD8 recognize peptides from intracellular 
pathogens that are passed to the APC surface by major histocompatibility complex 
(MHC) class I molecules. Peptide presentation to CD8+ T cells results in increase in 
numbers in the presence of B7 molecules expressed on APCs to produce cytotoxic T 
cells (CTLs) that can kill transformed tumor cells via production of cytotoxic 
molecules. CD4+ T cells recognize peptide antigens processed from pathogens 
multiplying in intracellular vesicles and those derived from ingestion of extracellular 
bacteria and toxins are carried to the cell surface by MHC class II molecules and 
presented to CD4+ T cells, which then receive a second signal from DCs provided by 
molecules of the B7 family to differentiate into the different subtypes of helper T cells 
(Th; type Th1 and Th2) (143). 
Co-stimulatory and co-inhibitory molecules 
T cells require two signals for activation: an antigen specific signal, involving the 
recognition of a peptide/MHC protein complex by the T cell receptor (described 
earlier), and additional costimulatory signals. Only when the T cell recognizes both 
the antigen and a costimulatory signal on APC an immune response is initiated. 
There are two main families of co-stimulatory molecules: B7/CD28 family, which 
belongs to larger superfamily of immunoglobulin proteins (120) and tumor necrosis 
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factor (TNFR)/TNF receptor (TNFR) family (82) (summarized in Table 1.3). Unlike the 
B7/CD28 family, that contains both co-stimulatory and co-inhibitory proteins, the 
members of TNF/TNFR family have only co-stimulatory function.  
Table 1.3: Co-stimulatory and co-inhibitory molecules in T cell function 
Receptor Expression Ligands (expression) Function in immune 
system 
B7/CD28 superfamily 
CD28 Constitutive T 
cells 
B7.1 (CD80), B7.2 
(CD86), Activated APC 
Immune stimulation: 
provides signal 2for 
initial survival and 
proliferation of naïve T 
cells 
ICOS Activated T cells B7RP1 (LICOS), ICOSL, 
on activated APC and 
some non-lymphoid 
tissues 
Immune cell 
differentiation: enhances 
T helper cytokine 
production , antibody 
class switch, germinal 
center formation 
CTLA-4 Activated T cells B7.1 (CD80), B7.2 
(CD86) 
Inhibitory: 
downregulates immune 
response 
PD-1 Activated T and B 
cells 
PD-L1, PD-L2, lymphoid 
and non-lymphoid tissues 
Inhibitory 
TNFR superfamily 
CD137  
(4-1BB) 
Activated T cells, 
activated DCs, 
activated NK cells 
CD137L (4-1BBL), on 
activated APCs 
Immune cell activation 
and survival, CD8+ T 
cell memory 
CD134 
(OX-40) 
Activated T cells 
(mainly CD4+ T 
cells) 
CD134L (OX-40L), on 
activated T, B, DC, 
vascular endothelial cell 
CD4+ T cell memory 
CD40 B cells, DC, 
Macrophages 
CD40L (CD154), on 
activated T cells, mainly 
CD4+ T cells 
B cell and DC activation 
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APC - antigen presenting cell; B7RP1 – B7-Related protein 1; CTLA-4 – cytotoxic T 
lymphocyte associated antigen-4; DC – dendritic cell; ICOS – inducible co-stimulator; L – 
ligand; NK – Natural killer cell 
The B7/CD28 superfamily is responsible for initial T cell expansion and short term 
survival (79). The TNFR superfamily is a group of receptors involved in enhancing T 
cell proliferation, cytokine production, and particularly survival (122). The lack of 
positive co-stimulatory ligands or the presence of inhibitory ligands has been 
suggested to contribute to poor anti-tumor T cell efficacy (31). Detailed function as 
well as in vivo manipulation of co-stimulatory and co-inhibitory molecules, which 
improves the ability of tumor-specific T cells to control and subsequently eradicate 
tumor, is described in the “Cancer immunotherapy” part. 
CD8+ T cells  
CD8+ T cells, also known as cytotoxic T lymphocytes (CTL), belong to a sub-group of 
T lymphocytes and represent the most critical effector cell of adaptive immunity. 
CD8+ T cells are recognized as cytotoxic after they become activated. To develop 
into activated effector CTL that can combat tumor cell, naïve CD8+ T cells need to 
recognize peptide antigens presented by MHC I molecules on activated APCs. MHC 
class I molecules are also expressed by non-classic APCs including all nucleated 
cells. This is very crucial as oncogenic viruses can infect almost all nucleated cells. 
CTLs expand under the influence of IL-2 over several hundred folds during a primary 
immune response and constitute a very efficient antigen-specific pool of effectors that 
are able to kill several targets leaving healthy cells untouched (67). 
Cytotoxic CD8+ T cells are armed with special cellular mechanisms and molecules 
that cause tumor cell destruction. After forming the immunological synapse between 
CD8+ T cell and its target, CTLs utilize one of the two main mechanisms to kill the 
tumor cell. The first pathway is a calcium-dependent release of specialized cytotoxic 
granules, such as perforin and granzymes, called perforin/granzyme pathway. 
These lytic granules transported to the tumor cell as one compound and are all 
required for effective cell killing. Immediately after CTL-target synapse formation, 
perforin (described originally for its pore forming properties) and granzyme are 
released from the granules by exocytosis into the junctional space between the two 
cells. As the perforin contact the target cell membrane, it undergoes a conformational 
change, polymerizes in the presence of calcium to form cylindrical pores, mediating 
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granzyme entry inside the target. There are different types of granzyme molecules 
that promote apoptosis of the target cell. Many target cells have a molecule known as 
the 6-phosphate receptor on their surface that also binds to granzyme B. Granzyme 
B/mannose 6-phosphate receptor complexes are then internalized and appear inside 
vesicles. In this case, perforin is necessary for releasing granzyme B from the vesicle 
into the cytoplasm of the target cell. Once it enters the cytoplasm of the target, 
granzyme B cleaves and activates caspases (especially caspase-3). Caspase-3 
activates a caspase proteolytic cascade, which eventually activates the caspase-
activated deoxyribonuclease (CAD). This nuclease is believed to be the enzyme that 
degrades the DNA. Other granzymes (A; K; N and etc.) are thought to promote 
apoptosis by targeting different cellular components (43, 67).  
The second pathway for CTL killing is the calcium-independent Fas ligand/ Fas-
mediated apoptosis (FasL/Fas). In this pathway FasL (CD95L), expressed on the 
CTLs, binds to their cognate receptor, Fas (CD95), expressed on the target tumor 
cells. The FasL/Fas engagement causes the activation of an initiator caspase in the 
target cell, which ultimately leads to DNA cleavage and cell death in a non-
inflammatory manner (43). 
CD4+ T cells 
CD4+ T cells, also called as helper cells, are subpopulation of T lymphocytes, which 
main function is to provide supporting signals to other immune cells, such as B cells, 
CD8+ T cells and macrophages either through secretion of cytokines or via direct 
interaction. Naïve CD4+ T cells recognize antigens presented by MHC class II 
molecules on activated APCs. APCs activation, mediated by PRR signaling, leads to 
upregulation of the MHC class II on their surface, as well as co-stimulatory molecules 
(CD80, CD86) and pro-inflammatory cytokines (such as tumor necrosis factor (TNF), 
IL-2, IL-1, IL-6 and IL-12) (131). As soon as the activated APCs migrate to tumor-
drLNs, they prime naïve CD4+ T cells, which in turn differentiate and polarize into 
effectors with different functions (Figure 1.1). 
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BCL-6 B cell lymphoma 6; EOMES -eomesodermin, FASL - FAS ligand; FOXP3 - forkhead 
box P3; GATA3 - GATA-binding protein 3; RORγt - retinoic acid receptor-related orphan 
receptor-γt; TCR - T cell receptor; TGFβ - transforming growth factor-β; TNF - tumor necrosis 
factor; adapted from (130). 
The differentiation of polarized effector CD4+ T cells is under the control of exclusive 
sets of transcription factors. The expression of these factors is highly depended on 
the signals provided by different cytokines. The original source of cytokines is from 
APCs. Some of the cytokines are produced by already differentiating CD4+ T cells 
and subsequently create a positive loop, which in turn enhances ongoing 
differentiation. 
T helper 1 (Th1) 
Th1 cells are implicated in host defense against intracellular viral and bacterial 
pathogens. By secreting such cytokines as interferon-gamma (IFN-γ), interleukin-2 
(IL-2), IL-10 and tumor necrosis factor-alpha/beta (TNF-α/β), these cells are 
responsible for maintaining pro-inflammatory T cell-mediated immunity. Pro-
inflammatory cytokines promote macrophage activation, cytotoxic CD8+ T cell 
Figure 1.1: Different subsets of CD4+ T cells 
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proliferation, nitric oxide production, leading to the phagocytosis and destruction of 
the pathogens. 
The master regulator for Th1 differentiation, the T-box transcription factor (T-bet), is 
involved in activating set of genes to promote differentiation of a particular 
phenotype. IL-27 signaling induces signal transducer and activator of transcription 1 
(STAT1)-dependent expression of T-bet, which promotes expression of IFN-γ and IL-
12 that then in turn stimulate STAT4-dependent IFN-γ production and further Th1 
differentiation. Excessive Th2-type immune responses have been implicated in the 
development of autoimmune diseases (148).  
T helper 2 (Th2)  
Th2 cells are involved in mediating non-inflammatory adaptive immune response. 
These cells are important for humoral immunity by promoting IgA, IgE and IgG 
immunoglobulins production by B cells. Th2 cells secrete following cytokines: IL-4, IL-
5, IL-6, IL-10, and IL-13 (83). Th2 differentiation occurs in the presence of IL-4 and 
either IL-2, IL-7. Exposure of activated naive CD4+ T cells to IL-4 induces STAT6-
dependent expression of GATA-3 and Growth Factor Independent-1 (GFI-1). GATA-
3, the master transcriptional regulator of Th2 cells, promotes IL-5 and IL-13 
expression, and along with GFI-1 stimulates the expansion of Th2 cells, while 
suppressing the differentiation of other T cell subtypes, in particularly Th1 cells. In 
addition to IL-4-induced activation of GATA-3, IL-2, IL-7 is required during Th2 
differentiation to activate STAT5, which cooperates with GATA-3 to promote T cell 
production of IL-4. IL-4 regulates clonal expansion of Th2 cells, and along with IL-13, 
promotes B cell production of IgE and alternative macrophage activation. 
Exaggerated Th2-type immune responses have been associated with the 
development of chronic allergic inflammation and asthma (83). 
Cytotoxic CD4+ T cell 
In addition to potent helper function, which CD4+ T cells provide to B cells and CD8+ 
T cells, there is a sufficient evidence to suggest that effector CD4+ T cells have 
strong anti-viral and anti-tumor roles that are independent of their helper activities. 
Strong immune protection mounted by CD4+ T cells. Interestingly, the cytotoxic 
activity of CD4+ T cell effectors does not depend on Th1 polarization, and expression 
of transcription factor Eomesodermin (Eomes), but not T-bet, may be crucial in 
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driving the development of cytotoxic CD4+ T cells in vivo (109). Eomes also a 
member of the T-box transcription factor family, which is important in regulating 
cytotoxic CD8+ T cells development and functions. Additionally, Eomes has been 
shown to be required for the upregulation of cytotoxic molecules (e.g. granzymes) in 
Th1 cells responding to staphylococcal enterotoxin A in the presence of agonist 
antibodies CD134 (OX40) and CD137 (4-1BB) (109). There are two distinct 
mechanisms through which cytotoxic CD4+ T cells promote tumor clearance. The 
release of pro-inflammatory cytokines, such as IFN-γ, TNF-α and IL-2, by CD4+ T 
cells help to coordinate an anti-viral and anti-tumor state in infected tissue. 
Additionally, cytotoxic CD4+ T cells can directly attack and destroy infected and tumor 
cells through diverse mechanisms, which are Fas/FasL-dependent and 
perforin/granzyme-dependent pathways (described earlier). Therefore, CD4+ T cells 
that acquire cytotoxic function can be considered as a separate CD4+ T cell subset. 
 
 
FASL - FAS ligand; NK – natural killer; TRAIL – TNF-related apoptosis-inducing ligand; TCR 
- T cell receptor; TRAILR – TRAIL receptor; (130). 
T helper 9 (Th9) 
Th9 cells are important for host defense against parasitic helminth infections, but 
may also have detrimental effects including contributing to the development of 
Figure 1.2: Antiviral functions of CD4+ T cells that are independent of their 
lymphocyte helper functions  
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chronic allergic inflammation, airway remodeling, and autoimmune disease. Th9 cells 
preferentially secrete high levels of IL-9, CCL17, CCL22, and IL-10. Master 
transcription factors that regulate distinct fate of Th9 cells are IRF4 and PU.1 (44, 
110). TGF-β was found to avert the differentiation of Th2 towards the development of 
Th9 cells (136). 
T helper 17 (Th17) 
Th17 cells contribute to host defense against extracellular bacteria and fungi. Th17 
cells develop from naive CD4+ T cells in the presence of TGF-β and IL-6. These 
cytokines induce the STAT3-dependent secretion of IL-21, IL-23 R, and the 
transcription factor, ROR gamma t. IL-21 and IL-23 regulate the formation and clonal 
expansion of Th17 cells, while ROR gamma t-induced gene expression leads to the 
secretion of IL-17, IL-17, and IL-22. Cytokines secreted by Th17 cells stimulate 
chemokine secretion by resident cells, leading to the recruitment of neutrophils and 
macrophages to sites of inflammation. These cells, in turn, produce additional 
cytokines and proteases that further impair the immune response. Persistent 
secretion of Th17 cytokines promotes chronic inflammation and may be implicated in 
the pathogenesis of inflammatory and autoimmune diseases (83). 
Regulatory T cells (Tregs) 
Tregs are specialized subpopulation of CD4+ T cells, which are naturally present in 
the immune system as 10-15% of CD4+ T cells in mice. The main function of Tregs, 
also known as suppressor T cells, is to maintain immune homeostasis. It implicates 
suppression of successful immune responses and keeps in check of self versus non-
self recognition. Failure of the latter results in autoimmune destruction of host cells 
and tissue (112). Like other T cells, one subset of Tregs matures in the thymus 
where they are characterized by the variable expression of CD4, CD25 and Foxp3. 
These are the natural Tregs. Natural Tregs express IL-2Rα chain (CD25) and the 
transcriptional repressor forkhead box protein 3 (Foxp3). The importance of Foxp3 is 
defined by genetic mutations in this molecule which result in a fatal autoimmune 
disorder known as immune dysregulation, Polyendocrinopathy, Enteropathy X-linked 
(IPEX) syndrome, which develops early in infancy (7). Additionally, natural Tregs are 
characterized by surface expression of Neuropilin-1 (Nrp-1), which was found to be 
selectively expressed on natural Tregs (152). Tregs that arises in the periphery are 
called inducible Tregs. This cell population is generated from naïve CD25+ or CD25- 
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T cells in the periphery upon antigen presentation by semi-mature DCs and under the 
influence of IL-10, transforming growth factor β (TGF-β) and possibly IFN-α (94). 
Higher numbers of CD4+ Tregs in cancer patients compared to normal healthy 
controls have been reported in recent years for many cancers, including head and 
neck, hepatocellular, gastric, breast, ovarian, lung, melanoma, renal cell, and 
pancreatic cancer (150). Studies investigating CD4+CD25+ cells show that in cancer 
patients, Tregs constitute 13% to 52% of the total number of CD4+ T cells (150). 
Increased numbers of Tregs have also been observed in numerous human and 
animal studies of chronic viral infections, including oncogenic viruses, in Hepatitis C 
virus (HCV) (11), HIV (5), EBV (87) and herpes simplex virus (HSV) (129) infections. 
The biological significance of these higher peripheral numbers of Tregs is a matter of 
debate. In EBV infected humans, induction of Treg inhibits CD4+ T cell responses to 
EBV proteins supporting viral persistence and promoting the induction of EBV-
associated tumors (94). 
 
 
Figure 1.3: Basic mechanisms used by Tregs (139) 
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There are four suppression mechanisms, which are utilized by Tregs (Figure 1.3). 
Tregs can srelease inhibitory cytokines, such as IL-10, TGF-β, and IL-35, and 
apply these soluble factors as a main mechanism of suppression (Figure 1.3a). 
Recent studies showed that Tregs may use perforin/granzyme-mediated 
cytotoxicity, which leads to apoptosis of effector T cells (Figure 1.3b). Metabolic 
disruption includes high-affinity CD25 dependent cytokine-deprivation-mediated 
apoptosis, cyclic adenosine monophosphate (cAMP)-mediated inhibition, and CD39- 
and/or CD73-generated, adenosine receptor 2A (A2AR)-mediated 
immunosuppression (Figure 1.3c). Mechanisms targeting DCs contain the 
modulation of maturation and function of DCs through lymphocyte-activation gene 3 
(LAG-3) –MHC-class-II-mediated suppression of DC maturation, and CTLA4–
CD80/CD86-mediated induction of indoleamine 2,3-dioxygenase (IDO), which itself is 
an immunosuppressive molecule made by DCs (Figure 1.3d) (139). 
Plasticity of CD4+ T cells 
Although the production of the specific cytokines , such as IFN-γ, IL-4 and IL-17 is 
commonly used to ascribe subsets (Th1, Th2 and Th17, respectively) to 
corresponding CD4+ T cells, accumulating evidence suggests that CD4+ T cells, are 
more plastic than previously estimated. Additionally, certain cytokines (for example, 
IL-10) can be produced by subpopulations of cells within multiple effector subsets. 
They all are capable of mediating direct anti-viral and anti-tumor functions, of 
providing help for B cells, of regulating immunopathology and of mediating cytotoxic 
killing of virus-infected or transformed cells. Certain CD4+ T cell subsets — 
particularly Tregs — are often defined less by their cytokine profile and more by their 
functional attributes. Foxp3 is an essential transcription factor required to manifest 
the Tregs phenotype and function (described earlier). Plasticity, in regards to Tregs, 
determines whether a Treg cell changes its functional capability and still maintains its 
fundamental Foxp3+ Tregs identity (113). Induced Tregs can readily switch to other T 
helper cell programs under certain cytokine conditions. For instance, induced Tregs 
can become IL-17-producing cells upon stimulation of IL-6 and IL-21. Th17 cells in 
turn can also convert into IFN-γ-producing Th1 cells or IL-4-producing Th2 cells when 
stimulated by IL-12 or IL-4, respectively. However, it is still unclear, whether natural 
Tregs can be converted to the effector CD4+ T cells and change their function. The 
effector T cells had been thought to be terminally differentiated lineages, but it now 
appears that there is considerable plasticity to gain different phenotype (158). 
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1.4 Cancer immunotherapy 
Cancer immunotherapy represents the most promising tumor-treatment approach 
since the development of the first chemotherapies in the late 1940s. It works through 
enhancing the innate powers of the immune system to locate and attack cancer. 
The prevailing techniques of cancer immunotherapy can be divided into two major 
clusters known as non-specific and antigen-specific therapies. 
1.4.1 Specific immunotherapy 
Specific immunotherapy can be attained by either adoptive transfer or vaccination. 
Adoptive transfer means the actual components of the immune system, which are 
already capable of producing a specific immune response, are transferred into the 
patients. Vaccination, on the other hand, involves the administration of a certain 
antigen to induce a specific immune response. 
1.4.2 Non-specific immunotherapy 
Non-specific immunotherapy refers to therapies that can stimulate the immune 
system by using a substance that activates or boosts immune cell function regardless 
of their antigen specificity. 
 
Figure 1.4: The cytokine milieu determines CD4+ T cell differentiation and 
conversion (158) 
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Cytokines 
A number of scientific studies have demonstrated the use of cytokines in 
immunotherapy that can lead to the destruction of tumors through one of following 
two general mechanisms: first, a direct antitumor effect or second, an indirect 
enhancement of the antitumor immune response. In the first method/mechanism, 
cytokines, such as the TNF-α, IFN- α, IFN- β, IL-4, and IL-6 interact directly with 
tumor cells to induce the latter to either commit suicide or to stop further growth. 
Although these cytokines are effective when considered as single agents, the 
administration of a cytokine cocktail can be even more potent as an anticancer agent 
due to the various synergistic effects stemming from the different cytokines. 
However, some cytokines can have hazardous side effects. For instance, TNF- α and 
IL-6 are able to suppress the growth of some tumors while actually promoting the 
growth of others. Therefore, any immunotherapeutic use of cytokines involves a 
careful calculation of the potential positive effects and the drawbacks of the 
procedure (78). 
Immune system checkpoints blockade 
An instrumental part of any immune system is its ability to keep itself from attacking 
other healthy cells in the body. To do so it uses ‘checkpoint’ molecules expressed on 
immune cells which need to be either activated or inactivated to launch an immune 
response. Cancer cells sometimes manage to bypass these checkpoints and avoid 
being targeted by the immune system. 
 CTLA-4 
Cytotoxic T lymphocytes antigen-4 (CTLA-4) is a member of the CD28 superfamily 
and is expressed on T cells after CD28 binding and activation (114). It normally acts 
as a type of “off switch” that helps to keep T cell in check and prevents the latter from 
attacking other cells in the body. The ligands for CTLA-4 – B7-1 and B7-2, are the 
same as for CD28 but with higher affinity  (75). CTLA-4 competes with CD28 and 
inhibits T cell proliferation and signaling. 
Ipilimumab is a monoclonal antibody that attaches to CTLA-4 and obstructs its ability 
to downregulate the immune system. This drug is used to treat malignant cancers, 
such as melanoma, which have been deemed to be inoperable or have disseminated 
and metastasized to other organs. This drug has demonstrated a survival benefit. 
However, the number of patients responding is limited. In addition, the severe side 
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effects from CTLA-4 blockade, such as diarrhea, skin rash, itching skin and 
heartburn, limit the drug usage even further (141). 
 PD-1/PDL-1 
The accumulation of experience in targeting CTLA-4 increased the interest in 
investigating additional immunologic checkpoints, such as the programmed cell death 
1/ programmed cell death ligand 1 (PD-1/PD-L1) pathway. PD-1 is an inhibitory 
receptor expressed on activated T cells, B cells, and natural killer cells (39). 
Compared to CTLA-4, it seems to be found more often in T cells in inflamed tissues 
and tumors, where it helps contain the immune response under control. It does this 
by attaching itself to PD-L1 (B7-H1), which is expressed on hematopoietic cells and 
in peripheral tissues including tumor, and to PD-L2 (B7-DC), whose expression is 
more restricted to hematopoietic cells (30). Tumor expression of PD-L1 acts as a 
protection against T cell-mediated killing through promoting T cell exhaustion. 
Notably, some cancer cells have large amounts of PD-L1 on their surface, which 
helps them evade immune attacks (160).  
The anti-PD-1 antibodies with the longest follow-up data are nivolumab and 
pembrolizumab. These drugs have demonstrated a high response rate in patient with 
melanoma (31, 32) as well as measurable superiority to chemotherapy (32). 
The tumor necrosis factor receptor family as a target for cancer 
immunotherapy 
In the past few decades, the generation of monoclonal antibodies targeting immune-
stimulating receptors has led to an increase anti-tumor immunity in cancer-bearing 
hosts resulting in therapeutic responses. The general principle regarding this therapy 
is that the function of T cells in cancer-bearing hosts is suppressed by the tumor 
microenvironment. Therefore, the immune stimulating antibodies help to overcome 
this immune suppression by promoting the function of APCs and T cells, which 
eventually results in tumor regression. (96). Many of the tumor necrosis factor 
receptor (TNFR) family members have been proposed as a potential immunotherapy 
targets. 
 CD137/CD137L 
The first of the TNFR family members that was identified as a possible 
immunotherapy target was CD137, also known as 4-1BB (92). CD137 is absent on 
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naïve T cells, but it is upregulated and continually expressed following T cell 
activation. It is also expressed on NK cells, and on various activated cells of 
hematopoietic as well as on non-hematopoietic cells including endothelial cells of 
some tumors. CD137 binds to its ligand, CD137L, which is expressed predominantly 
on activated APCs, such as macrophages, DCs, and B cells, but it can also be found 
on non-hematopoietic cells at sites of inflammation. This ligation results in activation 
of classic and non-classic nuclear factor kB pathways that promotes the higher 
production of anti-apoptotic molecules such as Bcl2 and Bcl-xl and protects tumor 
antigen specific cells from activation-induced cell death. CD137/CD137L interaction 
also improves proinflammatory cytokines expression, such as IL-2, TNF-α, IL-6, and 
IL-12 (144). More recently, a connection between CD137 signaling and the T cell 
master transcription factor Eomes has been revealed from observations of high 
expression levels of Eomes in CD4+ and CD8+ tumor-infiltrating T cells following 
CD137 agonist therapy in a mouse melanoma tumor model (28). Eomes, member of 
the T-box family of transcription factors, have been implicated as critical determinants 
of effector T cell activity to various infectious and tumors. 
In addition to CD137’s role in promoting proliferation and survival of antigen specific 
T cells, CD137 can be expressed on tumor cells and vascular endothelium (144). 
This suggests the agonist CD137 antibodies could promote direct tumor cell death 
via antibody dependent cell mediated cytotoxicity (ADCC) and tumor cell 
phagocytosis (4). 
Clinical trials are exploring the importance of anti-CD137 therapy in patients with 
different malignancies. A fully humanized anti-CD137, PF-05082566, is currently 
being tested in clinical trials as either a single agent in patients with advanced cancer 
or in combination with rituximab in patients with Non-Hodgkin’s lymphomas 
(NCT01307267) (21). 
 CD134/CD134L 
CD134, also known as OX-40, is expressed on T cells, NK cells and NKT cells, and 
neutrophils. The ligand, CD134L, is predominantly expressed on activated DCs, as 
well as on macrophages, B cells, Langerhans cells, smooth muscle cells, 
endothelium and mast cells. CD134/CD134L interaction delivers strong co-
stimulatory signal, leading to an enhanced cell proliferation, survival, effector function 
and migration (46). The importance of CD134 signaling was demonstrated in tumor-
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bearing mice where up to 80% of the animals were cured depending on the tumor 
model (145). CD134+ T cells were present in a wide variety of human malignancies 
(138), which promoted translation of anti-CD134 therapy to the clinic.  
 CD40/CD40L 
CD40 was mainly considered a molecule essential for humoral immunity, since it was 
initially discovered on B cells and DCs. However, CD40/CD40L axis turned out to be 
also important for development of T cell response. It promotes functional maturation 
leading to an increase in antigen presentation and cytokine production, and a 
subsequent increase in the activation of antigen specific T cells. Targeting CD40 with 
an agonist monoclonal antibody has been tested in patients with both hematological 
cancers and solid tumors (8, 15).  
1.5 Retroviruses 
Most retroviruses are RNA viruses that can cause either leukemia (malignancy of 
lymphoblasts, myeloblasts, or erythroblasts) or sarcoma (solid tumors that can 
metastasize in any organ of the body). 
The retrovirus genome consists of two molecules of RNA, which are physically linked 
by hydrogen bonds. In addition, there is a specific type of transfer RNA (tRNA) 
present in all particles that is required for replication. The genomes of simple 
retroviruses encode the virion capsid/nucleocapsid (gag) proteins, that compose the 
core of the virus; the enzymes needed for genome replication: reverse transcriptase, 
that transcribes the RNA genome into its DNA component; and integrase; that 
catalyzes the integration of the double-stranded DNA copy into the host genome, 
Pol/In; and the envelope proteins (env) that bind the cell surface molecules used for 
virus entry.  
Retroviruses generally replicate by binding to a cellular receptor and causing 
transcription of genomic RNA into proviral DNA and integration of proviral DNA into 
chromosomal DNA. Latency may be established at this point, or transcription may 
occur to produce new genomes and mRNA. The virus is released by budding, usually 
without cytopathology (85). 
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1.5.1 Mechanism of retroviruses’ oncogenesis 
The mechanisms by which oncogenic retroviruses induce tumor formation vary. 
Tumor formation often involves activation of a cellular oncogene and down-regulation 
of tumor suppressor genes. There are three major classes of oncogenic retroviruses, 
the non-acute transforming viruses, the acute transforming viruses and the trans-
acting viruses. 
 
Table 1.1.4: Major categories of oncogenic retroviruses (101) 
Category Occurance 
(incubation 
period) 
Mechanism of 
transformation 
(clonality) 
Replication 
competence 
Examples 
Non-acute 
transforming 
In nature, more 
common  
(years) 
Insertional up-
regulation of cellular 
proto-oncogenes 
(clonal) 
Competent  
F-MuLV, ALV, 
FeLV 
Acute 
transforming 
In nature, 
uncommon 
(weeks) 
Action of viral 
oncogenes 
(polyclonal) 
Defective, 
requires helper 
virus 
ASV, MSV, 
FeSV, SFFV 
Trans-acting 
transforming 
In nature, 
uncommon 
(years) 
Transactivation by 
viral accessory 
genes (oligoclonal) 
Competent HTLV-1, BLV 
 
ALV - Avian leukemia virus; ASV - Avian sarcoma virus; BLV- Bovine leukemia virus; FeLV - 
Feline leukemia virus; FeSV - Feline sarcoma virus; HTLV - Human T-cell leukemia virus; F-
MuLV – Friend murine leukemia virus; SFFV – Spleen focus forming virus; MSV - Murine 
sarcoma virus. 
Non-acute transforming retroviruses: insertional mutagenesis 
Tumorigenesis results from mutations caused by either promoter/enhancer insertion 
or by insertional mutagenesis. During this process viruses can activate cellular proto-
oncogenes by inserting a viral long terminal repeat (LTR) close to the oncogenes to 
induce tumor. Transformation due to the effect of the LTR can be effected in two 
ways – promoter insertion and enhancer activation. In promoter insertion, the DNA 
provirus is integrated upstream and in the same orientation to a proto-oncogene (a 
normal cellular gene that can influence cell growth). Transcription is initiated in an 
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LTR of the provirus and reads through the downstream cellular gene, increasing its 
rate of transcription. If the cellular gene that is up-regulated has an influence on 
cellular growth, then transformation may occur. The formed tumors are typically 
clonal but the transformed cells will depend upon the genomic site of insertion (Fig 
1.2 a). For enhancer activation - the provirus DNA is oriented to read away from the 
cellular gene, the enhancer sequences in the provirus may bind cellular factors that 
“open” condensed DNA and enhance transcription of neighboring cellular genes 
regardless of their orientation (Fig 1.2 b). If the gene influences cellular growth, it 
results in transformation. Since enhancer activation can occur at more sites in the 
cellular genome, it is a more common phenomenon than promoter insertion (101).  
 
 
a) Promoter insertion, b) Enhancer activation  
 
Acute transforming retroviruses: viral oncogenesis 
Acute-transforming retroviruses are typically replication defective as they have lost 
their genes such as gag and env during an ancestral recombination event, and they 
rapidly induce tumors because of the viral oncogenes that they carry (v-onc). These 
oncogenes possess a specific transforming activity at a high level. Most v-onc genes 
are derived from proto-oncogenes (c-onc). Hence, they can grow only in the 
presence of a replication-competent non-transforming retrovirus (101). 
 
a) 
b) 
Figure 1.5: Mechanisms of transformation (101) 
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Trans-acting retroviruses: viral accessory genes 
These retroviruses encode several accessory genes that are not only essential for 
their replication but also play a role in their transforming activity. However, the 
mechanism of oncogenesis is complex and there is also the requirement of 
subsequent non-viral genetic events for tumor formation. HTLV-1 is the best studied 
example trans-acting retroviruses (101).  
1.5.2 Friend virus complex as a model to study immunity to retroviruses 
Friend virus-induced disease  
Charlotte Friend discovered the Friend viral erythroleukemia in 1956 and it has since 
become a reliable model for understanding host genetic barriers to retroviral 
diseases. It has assisted in finding mouse genes that control susceptibility to virus-
induced cancer and has also been a good model for testing anti-retroviral drugs. 
Friend virus (FV) belongs to the family of retroviruses. FV is a complex of two 
viruses: Friend murine leukemia virus (F-MuLV), a replication-competent helper virus 
that is nonpathogenic in adult mice; and spleen focus-forming virus (SFFV), a 
replication-defective virus that is the pathogenic component (70). SFFV cannot 
produce its own particles because its gag gene is defective; therefore, it spreads by 
being packaged in F-MuLV-encoded particles produced in cells co-infected by both 
viruses. Pathology in susceptible adult mice is characterized by a polyclonal 
proliferation of erythroid precursor cells, which results in massive splenomegaly. 
Tumor development is a three-step process that is well characterized on a molecular 
level: 
A false proliferative signal induced by the binding of SFFV gp55 envelope 
glycoproteins to erythropoietin receptors on nucleated erythroid cells causes 
splenomegaly (80). In this way, the infection produces a massively expanded 
population of actively dividing susceptible to viral infection cells. Ultimately, SFFV 
genomes integrate into two specific sites common to FV-induced erythroleukemias: 
Spi1 and p53 (70). Insertional mutagenesis-mediated deregulation and 
overexpression of the Spi1 proto-oncogene, in combination with integration-induced 
inactivation of the p53 tumor suppressor gene, result in fully malignant 
erythroleukemias in susceptible mice. The resistant strains of mice are those with a 
certain MHC background (C57BL/6) that mount immune responses with sufficient 
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potency and speed to prevent the accumulation of transformed cells due to their 
antigen-presenting cells can present immunodominant T cell epitopes of FV (52).  
FBL-3 model and immune response 
FBL-3 cells are an FV-induced tumor cell line of C57BL/6 origin (41). FBL-3 cells do 
not produce infectious FV, but represent a highly immunogenic FV-transformed 
tumor cell line that expresses immunogenic FV antigens (18, 64). The antigens that 
are therefore recognized by protective immune cells are viral antigens expressed by 
virus-transformed tumor cells and are presented by MHC molecules.  
Previous studies used this model, where mice were inoculated intraperitoneally (i.p.) 
with FBL-3 cells and died 1-2 weeks later with progressive ascites, splenomegaly, 
and lymphadenopathy (47). The work on this model has demonstrated that: (1) both 
CD4+ and CD8+ T cells can independently promote tumor elimination in the absence 
of the contribution by T cells of the other phenotype; (2) the major antitumor effect of 
the CD4+ T cells results from the recruitment and activation of other effector cells, 
particularly macrophages; (3) the induction of tumor-specific antibody responses 
following T cell transfer is not an essential component of tumor eradication; (4) NK 
cells are not important in tumor elimination (48). 
However, at that time nothing was known about the Tregs and therefore, population 
of CD4+ T cells was not divided into the different compartments and the role of those 
cells was not determined in the FBL-3 model. Only in 2001 Iwashiro et al. 
demonstrated that mice persistently infected with FV develop approximately twice the 
normal percentage of splenic CD4+CD25+ T cells and lose their ability to reject 
subcutaneous (s.c.) implantation of FBL-3 cells (64) due to a dysfunction of antigen-
specific CD8+ T cells (154). In contrast, in uninfected mice after s.c. implantation of 
FBL-3 cells, the tumor grows locally and subsequently regresses in a CD8+ T cell 
dependent manner over a time period of 20 days (64). Later on it has been shown 
that during FBL-3 tumor rejection Tregs suppress cytotoxic CD4+ T cells when CD8+ 
T cells are not active (2).Previously we showed that in the absence of CD8+ T cells, 
CD4+ T cells could not control tumor development whereas additional ablation of 
Tregs enabled these cells to eliminate the tumor. This dual treatment augmented 
production of cytokines and cytotoxic molecules by CD4+ T cells and increased 
cytotoxic CD4+ T cell responses. Therefore, the capacity of tumor-reactive CD4+ T 
cells to reject tumors largely depends on the regulatory effect of CD4+ Tregs (2). 
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2 AIM AND SCOPE OF WORK 
Oncogenic viruses, such as retroviruses, hepatitis viruses and papilloma viruses are 
associated with 15% to 20% of all human malignancies. In spite of advances in the 
development of immune therapeutic strategies to combat cancer, the underlying 
mechanisms of immunotherapies against virus-induced cancer are not well 
understood. In the current study, we have used the highly immunogenic FV-induced 
FBL-3 tumor cell line as a model to examine the immunological mechanisms of tumor 
control in the course of costimulatory immunotherapy. CD137 (4-1BB) is an 
activation-induced costimulatory molecule on T cells that upregulates survival genes, 
enhances cell division and induces cytokine and cytotoxin production by tumor-
specific T cells. CD8+ T cells are important in the immune control of many tumors. In 
our model, complete rejection of FBL-3 tumor cells in C57BL/6 mice also depends on 
CD8+ CTLs. CD4+ T cells play an important role in facilitating help for effector CD8+ T 
and B cell responses against tumor antigens. Additionally, CD4+ T cells can also play 
a direct protective role in tumor rejection. However, regulatory T cells (Tregs) are 
known suppressors of anti-tumor immune responses and are often recruited by tumor 
cells to evade T cell mediated destruction. In regard to the FBL-3 tumor model, Tregs 
inhibit effector CD4+ T cell responses during tumor rejection. Interestingly, some 
Tregs retain a degree of plasticity, and under certain conditions may change 
(“reprogram”) to adopt a pro-inflammatory phenotype. It has been described that in 
addition to being expressed on activated effector T cells, CD137 is also expressed on 
Tregs. It is still unclear, however, what the effect of activation of the CD137 signaling 
pathway in Tregs is.  
Thus, the focus of this PhD study was to investigate the influence of CD137 agonist 
antibody on both the CD4+ T cell and Tregs compartments during virus-induced 
tumor formation. For this purpose, it was important to determine the phenotype 
acquired by CD4+ T cells following CD137 agonist therapy by analyzing the 
expression of various activation, differentiation, and proliferation markers. Moreover, 
it was of interest to determine the cytotoxicity of those cells. Furthermore, it was 
important to define the origin of the expanded Tregs after αCD137 treatment, as 
knowledge on this topic will provide new concepts to therapeutically interfere with 
Tregs expansion. 
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Therefore, our study contributes to the existing knowledge on CD137 agonist 
immunotherapy of cancers by exploring the significance of effector CD4+ T cells and 
by providing new important information about possible Tregs plasticity. 
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3 MATERIALS 
3.1 Laboratory animals 
3.1.1 Wild-type mice  
C57BL/6 (B6)
  
Resistance genotype H-2b/b, Fv1b/b, Fv2r/r, Rfv3r/r Harlan 
Winkelmann GmbH, Borchen, Germany. 
 
3.1.2 Congenic mice and transgenic mice 
CD45.1-congenic 
B6 
B6.SJL-Ptprca Pep3b/BoyJ, Inbred at Central Animal 
Laboratory, University Hospital Essen, Germany. 
 
B6NU-F B6Cg/NTac-Foxn1nuNE10. Foxn1nu mutation backcrossed 
to the C57BL/6NTac inbred strain. The deficiency in T cell 
function allows athymic mice to accept and grow 
xenografts as well as allografts of normal and malignant 
tissues. Taconic company. 
 
MHC class II 
knockout 
B6.129S2-H2dlAb1-Ea/J. Mice that are homozygous null for 
MHC class II genes H2-Ab1, H2-Aa, H2-Eb1, H2-Eb2, H2-
Ea. A dramatic decrease is observed in the number of CD4 
positive T cells in thymus, spleen and lymph nodes. This 
strain should serve as a suitable recipient of xenogenic 
Class II MHC transgenes allowing the engineering of 
mouse models of human MHC Class II-associated 
diseases. 
 
DEREG mice Created by Dr. Tim Sparwasser’s group (Institut für 
Medizinische Mikrobiologie, Immunologie und Hygiene, 
Technische Universität München, Munich, Germany) and 
maintained at animal facilities of University Hospital Essen.  
DEREG (depletion of regulatory T cell) mice were 
generated from bacterial artificial chromosome (BAC) 
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technology. These mice express a diptheria toxin receptor 
(DTR) enhanced green fluorescent protein (eGFP) fusion 
protein under the control of the foxp3 locus. Usage of 
DEREG mice allows both detection and inducible depletion 
of Foxp3+ Treg cells.  
 
All mice used were sex-matched and were 8-16 weeks of age at the beginning of 
experiments. The central animal laboratory kept the mice under specific pathogen-
free (SPF) conditions which were maintained for the entire experimental phase. 
The mice had free access to drinking water and standard food.  
3.2 Cell line 
FBL-3 is an FV-induced tumor cell line derived from a C57BL/6 mouse (41). FBL-3 
cells were maintained in complete RPMI medium supplemented with 10% FCS 
and 0.5% Penicillin/Streptomycin.  
3.3 Equipment and materials 
The equipment and materials used in this study are listed in Tables 3.1 and 3.2 
below. 
Table 3.1: Equipment 
Item Manufacturer 
Biofuge fresco Heraeus, München 
Centrifuge 5415 C Eppendorf, Hamburg 
CO2 incubator        Thermo, Dreieich 
Freezer LIEBHERR, Ochsenhausen 
Heating block            Grant, QBC 
Infrared lamps  Phillips, Amsterdam 
Laminar flow  KOJAIR®, Meckenheim 
LSRII flow cytometer                                           Becton Dickinson, Heidelberg 
Megafuge 1.0R Heraeus, München 
Neubauer cell counting chamber  Becton Dickinson, Heidelberg 
Reflected-light microscope CK 2     Hund, Wetzlar 
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Refrigerator   LIEBHERR, Ochsenhausen 
Single channel pipettes (10, 20, 100,  
200, 1000 µl) 
Eppendorf, Hamburg 
Sorvall centrifuge fresco Thermo, Dreieich 
 
Table 3.2: Materials 
Material Manufacturer 
Beakers Schott, Mainz 
Cannulae (G23; G25; G27) Becton Dickinson, Heidelberg 
Cell culture flasks (T25; T75; T175) Greiner bio-one, 
Frickenhausen 
Cell culture plates, sterile (6; 24 and 96 well) Greiner bio-one, 
Frickenhausen 
Cell microstrainer (70 µm) Falcon BD, Heidelberg 
Disposable syringes (5 ml; 10 ml) B. Braun, Melsungen 
Erlenmeyer flasks Schott, Mainz 
FACS tubes  Becton Dickinson, Heidelberg 
Forceps, pointed and curved Oehmen, Essen 
Microtest™ cell culture plates, 96 wells Falcon BD, Heidelberg 
Parafilm American National Can, 
Chicago 
Plastic pipettes (sterile; 1 ml; 5 ml; 10 ml; 25 
ml) 
Greiner bio-one, 
Frickenhausen 
PP screw-cap tubes (15 ml; 50 ml) Greiner bio-one, 
Frickenhausen 
Reaction tubes (1,5 ml; 2 ml) Eppendorf, Hamburg 
Scissors, large and small Oehmen, Essen 
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U-shaped microplates (96 wells) Greiner bio-one, 
Frickenhausen 
3.4 Chemicals and media 
Unless not otherwise mentioned, the following chemicals listed were procured 
from the companies Applichem, Merck, Roth and Sigma. 
autoMACS run and wash buffer (Miltenyi Biotec), bovine serum albumin (BSA), 
brefeldin A (BFA), calcium chloride, dextran, dimethyl sulfoxid (DMSO), ethanol, 
ethylendiaminetetraacetic acid (EDTA), FACS Clean (BD Bioscience), FACS Flow 
(BD Bioscience), FACS Rinse (BD Bioscience), fetal calve serum (FCS) 
(Biochrom), Ficoll (GE Healthcare), 37 % formaldehyde, formalin, incidine 8%, 
isopropanol, L-Glutamine, penicillin-streptomycin (PenStrep), phosphate buffered 
saline (PBS) (Gibco), RPMI-1640-Media (Gibco), trypan blue, trypsin-EDTA, 
Cytofix/Cytoperm [BD Pharmingen], CFSE Cell Proliferation Kit [Invitrogen], Foxp3 
staining kit [eBioscience]. 
3.5 Antibiotics 
Ampicillin   (Sigma) 
Penicillin / Streptomycin (Gibco) 
3.6 Buffers and Media 
All solutions and buffers (unless otherwise mentioned) were prepared using 
double distilled water (see Table 3.3).  
Table 3.3: Buffers and media 
Description Composition 
Culture medium 500 ml RPMI 1640 (Gibco) 
10% FCS (Gibco) 
0.5% Penicillin/Streptomycin mixture 
FACS buffer PBS 
0.02% Na-azide 
0.5% BSA 
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Freezing mediums 40% FCS 
10% DMSO 
50% RPMI medium 
MACS buffer PBS supplemented with 0.5 % BSA and 2 mM EDTA 
PBBS 1 l Phosphate buffered saline (PBS) 
1.0 g glucose 
 
3.7 Antibodies 
Table 3.4: Antibodies for flow cytometry 
Antibodies  Clone 
Surface antibodies  
CD11a –PE; rat anti-mouse antibody [eBioscience] M17/4 
CD11b (Mac-1) -FITC; rat anti-mouse antibody [eBioscience] WT.5 
CD137-PE; monoclonal rat anti-mouse [BD Pharmingen] 1AH2 
CD25-perCP-Cy5.5; monoclonal rat anti-mouse antibody PC61 
CD28 Purified anti-mouse antibody 37.51 
CD43-FITC monoclonal rat anti-mouse antibody 1B11 
CD43-PE; monoclonal rat anti-mouse antibody [eBioscience] 1B11 
CD45.1-APC; monoclonal rat anti-mouse antibody [eBioscience] A20 
CD45.1-FITC; monoclonal rat anti-mouse antibody [eBioscience] A20 
CD45.2- eFluor® 450; monoclonal rat anti-mouse antibody 
[eBioscience] 
104 
CD4-AF700; monoclonal rat anti-mouse antibody [eBioscience] RM4-5 
CD4-eFluor 605; monoclonal rat anti-mouse antibody 
[BioLegend] 
RM4-5 
Fc block; Affinity purified anti-mouse CD16/CD32 [eBioscience] 93 
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CD8a-PerCP; monoclonal rat anti-mouse antibody [eBioscience] 53-6.7 
KLRG-1-Brilliant Violet 421; monoclonal rat anti-mouse/human 
antibody [BioLegend] 
2F1 
Neuropilin-1-APC; monoclonal rat anti-mouse antibody [R&D 
sytems] 
761705 
Surface antibodies  
CD154 –PE; monoclonal rat anti-mouse antibody [eBioscience] MR1 
Eomes- eFluor 450; monoclonal rat anti-mouse antibody 
[eBioscience] 
Dan11mag 
Eomes- PerCP-eFluor® 710; monoclonal rat anti-mouse antibody 
[eBioscience] 
Dan11mag 
Foxp3-APC; monoclonal rat anti-mouse antibody [eBioscience] FJK-16S 
Foxp3-FITC; monoclonal rat anti-mouse antibody [eBioscience] FJK-16S 
Foxp3-PE; monoclonal rat anti-mouse antibody [eBioscience] NRRF30 
Granzyme B–APC; monoclonal anti-human antibody [Invitrogen] GB12 
Helios–eFluor 450; anti-mouse/human antibody [BioLegend] 22F6 
IFN-γ-FITC; monoclonal rat anti-mouse antibody [eBioscience] XMG1.2 
IL-2–eFluor 450; anti-mouse antibody [eBioscience] JES6-5H4 
Ki67-PE-Cy7; monoclonal rat anti-mouse/human antibody 
[eBioscience] 
SolA15 
T-bet-PE-Cy7; monoclonal mouse anti human/mouse antibody 
[eBioscience] 
eBio4B10 
TNF-α–Pe-Cy7; rat anti-mouse antibody [eBioscience] MP6-XT22 
 
3.8 Fluorochromes 
The antibody-coupled fluorochromes and their absorption- and emission maxima 
are listed in Table 3.5. 
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Table 3.5: Characteristics of fluorochromes 
Flurophore Abbreviation Absorptio
n (nm)  
Emission 
(nm) 
Alexa flour 488 AF488 488 519 
Alexa flour 647 AF647 650 647 
Alexa Fluor 700  AF 700 633 723 
Allophycocyanin APC 633 660 
APC-cyanine7 APC-Cy7 650 774 
Brilliant violet 421 BV421 407 421 
Brilliant violet 605 BV605 405 605 
eFlour 650 eF650 407 650 
Eflour 780 eF780 633 780 
eFluor 450 eFluor 450 405 450 
Fluorescein isothiocyanate FITC 488 518 
Green fluorescent protein GFP 509 395/475 
PE-cyanine5 PE Cy5 660 670 
Peridinin-chlorophyll-protein complex  PerCP 488 675 
Phycoerythrin PE 488 575 
Phycoerythrin–Cy7 PE Cy7 488 785 
 
3.9 Standard kits 
Table 3.6: Standard kits 
Kit Manufacturer 
Cytofix/cytoperm intracellular staining kit BD Pharmingen, Heidelberg, Germany 
Foxp3 staining set eBioscience, San Diego, USA 
Mouse CD4+ T cell isolation kit II Miltenyi Biotec, Bergisch Gladbach, 
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Germany 
 
3.10 Depletion antibodies 
 
CD8+ T cell depletion antibody Clone 169.4.2.1, produced by YTS 
169.4.2.1 hybridoma cell line. 
 
CD4+ T cell depletion antibody Produced by YTS 191.1 hybridoma cell 
line 
3.11 Treatment reagents 
InVivoMAb anti m CD137 CD137 antibody, Clone LOB12.3, 
purchased from BioXcell. 
 
Diphtheria toxin (DT) Diphtheria toxin, Corynebacterium 
diphtheria – Calbiochem, purchased from 
Merck. 
 
3.12 MHC II tetramer 
The MHC class-II tetramer was provided by the NIH Tetramer Facility  
APC-labelled (I-Ab) MHC class II tetramers loaded with I-Ab-restricted MoMSV-
envelope epitope (H19-Env) derived peptide (EPLTSLTPRCNTAWNRLKL) (121). 
MHC class-II tetramers were provided by NIH tetramer core facility used for the 
detection of I-Ab FV envelope specific CD4+ T cells (Emory University, Atlanta, 
USA). 
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4 METHODS 
4.1 Animal trials 
The animal experiments were conducted according to the guidelines of the 
Federation of European Laboratory Animal Science Association. 
4.2 Tumor challenge 
Mice were shaved on the right flank and 1×107 FBL-3 tumor cells were injected 
subcutaneously (s.c.) in 100 μl of PBS through a 27-gauge needle on day 0. In order 
to verify tumor volume by external caliper, the greatest longitudinal diameter (length) 
and the greatest transverse diameter (width) were determined. Tumor size based on 
caliper measurements were calculated by formula: tumor area (cm2) = 𝜋 ∗ 𝑎 ∗ 𝑏, 
where a = half of length and b = half of width. After 4, 6, 8, 11, 15, and 20 days,On 
day 6 mice were sacrificed, and drLNs (inguinal) were resected. 
 
4.3 In vivo depletion of lymphocyte subsets and antibody treatment 
Mice were depleted of CD8+ T cells by intraperitoneal (i.p.) injection of 0.5 ml of 
supernatant from the hybridoma cell line 169.4 producing a CD8a-specific 
monoclonal antibody. CD8 depletion was started at day 0 and carried out every other 
day for the tumor growth analysis until mice were sacrificed due to the progressive 
tumor growth, or four times (on day 0, 2, 4, 6) for the experiments where mice were 
sacrificed at day 6 post tumor inoculation. The treatment depleted more than 90% of 
the CD8+ T cells in lymph nodes. 
Depletion of Tregs was done in DEREG mice by i.p. injection of 0,5 μg DT (Merck) 
diluted in endotoxin-free PBS three times on every third day starting at day -1 . The 
treatment depleted more than 95% of the CD4+ eGFP+ T cells in lymph nodes of 
DEREG mice.  
To deplete CD4+ T cells, mice were injected i.p. with 0.5 ml supernatant from the 
hybridoma cell line YTS 191.1 producing a CD4-specific monoclonal antibody. 
Depletion was carried out every other day starting at day 0. The treatment depleted 
more than 90% of the CD4+ T cells in lymph nodes. 
The mAb YTS191.1 was of immunoglobulin G2b isotype and was produced and used 
as ascites fluid or culture supernatant fluid. The hybridoma cell line was a kind gift 
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from Dr. Kim Hasenkrug (Laboratory of Persistent Viral Diseases, Rocky Mountain 
laboratories, NIAID, Montana, USA), and was stored in liquid Nitrogen chamber for 
later use.  
The αCD137 (LOB 12.3) used in vivo were produced by Bioxcell. Dosing per injection 
was 100 μg administered i.p. every other day from day 0 three times. 
 
 
4.4 Flow cytometry 
Flow cytometry is a method for analyzing expression of cell surface and intracellular 
molecules, characterizing and defining different cell types. It allows simultaneous 
multi-parameter analysis of single cells. It is predominantly used to measure 
fluorescence intensity produced by fluorescent-labeled antibodies detecting proteins 
or ligands that bind to specific cell-associated molecules.  
 
4.4.1 Methodology of flow cytometry 
A flow cytometer includes three main systems: fluidics, optics, and electronics (61) 
(Fig 4.2). 
Figure 4.1: Treatment and T cell depletion protocol 
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 The fluidics system hydrodynamically focuses the cell stream to the laser 
beam for examination. 
 The optics system includes lasers to light the particles in the sample stream 
and optical filters, which are used to direct the light signals to the detectors. 
 The electronics system converts the detected light signals into electronic 
signals that can be processed by the computer.  
 
(1) Forward-scatter detector, (2) side-scatter detector, (3) fluorescence detector, (4) filters 
and mirrors, and (5) charged deflection plates (66). 
 
Light scattering 
Light scattering takes place when a particle deflects incident laser light. Factors that 
affect light scattering include the cell's membrane, nucleus, and any granularity of the 
cell. Cell shape and surface topography are also important (65). Forward-scattered 
light (FSC) is proportional to cell size. FSC is a measurement of mostly diffracted 
light and is detected just off the axis of the incident laser beam in the forward 
direction by a photodiode.  
Side-scattered light (SSC) is proportional to cell granularity or internal complexity. 
SSC is a measurement of a light that occurs at any interface within the cell where 
there is a change in refractive index. SSC is collected at approximately 90 degrees to 
Figure 4.2: Principle of flow cytometry 
METHODS 
41 
the laser beam by a collection lens and then redirected to the appropriate detector 
(61) (Fig 4.3).  
 
(61) 
Fluorescence 
A fluorescent compound (fluorochrome) absorbs light energy over a range of 
wavelengths that is characteristic for that compound. This absorption of light results 
in an electron in the fluorescent compound rising to a higher energy level. The 
excited electron quickly goes back to its ground level, emitting the excess energy as 
a photon of light. This transition of energy is called fluorescence (61). These methods 
enable a quantitative investigation of the surface molecules. The basis for this is an 
antigen antibody reaction conducted with fluorescently-marked antibodies which are 
aimed at particular surface molecules. The single cell suspensions are analysed by 
flow cytometry (Fig 4.4). 
 
Figure 4.4: Specific binding of fluorochrome-labelled antibodies to cell surface 
antigens 
Figure 4.3: Identification of cells based on FSC v/s SSC 
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Depicts cell characteristics with respect to expression profile of 2 molecules, e.g., in this blot 
with CD8 on the y-axis and CD4 on the x-axis.  
Signal detection 
Light signals are generated as particles pass through the laser beam in a fluid 
stream. These light signals are converted to electronic signals (voltages) by 
photodetectors and then assigned a channel number on a data plot. A voltage pulse 
is created when a particle enters the laser beam and starts to scatter light or 
fluorescence. Once the light signals, or photons, strike one side of the photomultiplier 
tube (PMT) or the photodiode, they are converted into a proportional number of 
electrons that are multiplied, creating a greater electrical current. The electrical 
current travels to the amplifier and is converted to a voltage pulse. The highest point 
of the pulse occurs when the particle is in the center of the beam and the maximum 
amount of scatter or fluorescence is achieved. As the particle leaves the beam, the 
pulse comes back down to the baseline (61) (Fig 4.5).  
 
4.5 Preparation of single cell suspensions of lymph nodes 
For the removal of lymph nodes, required number of mice were anaesthetised with 
Isofluran® and killed by cervical dislocation. Lymph nodes were collected in 6-well 
plates kept on ice. Each lymph node was homogenised using a sterile sieve to make 
single cell suspension of lymph node cells using a sterile plunger of a 5 ml syringe. 
The thicker components were removed and the single cell suspension was 
transferred into a 50 ml tube. The lymph node suspension was filled up to 5 ml with 
PBBS. An aliquot was taken from each suspension to count viable cells by Trypan 
blue exclusion assay. The reactivity of trypan blue is based on the fact that the 
chromopore is negatively charged and does not interact with the cell unless the 
Figure 4.5: Formation of a voltage pulse 
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membrane is damaged. Thus, all the cells, which are not colored are viable. An 
aliquot of cells was diluted with 0.4% Trypan blue stain and 10 µL of the diluted cell 
solution was transferred onto the Neubauer cell counting chamber and cover-slipped 
to be examined under microscope (at 10x) for cell counting. Formula for counting 
number of viable cells for the total cell concentration: 
Numbers of cells/ml = numbers of cells over a large square X dilution factor 
Meanwhile, the suspensions in the tubes were centrifuged at 300 x g at 10°C for 8 
minutes. The cell pellet was re-suspended with PBBS to a desired final concentration 
of lymph node cells of 1 x 108 cells/ml. 
4.6 Staining of cells and FACS analysis 
1x106 cells from each tissue were suspended in FACS buffer, centrifuged for 5 min 
with 300 x g at room temperature and the supernatant was removed. The cell pellet 
was re-suspended in 100 µl FACS buffer containing 0.5 - 2 µl conjugated antibodies 
to various surface molecules and incubated in the dark for 30 min at 4°C. After a 
double rinse in FACS buffer, the cells were re-suspended with 400 µl FACS buffer. 
Data were acquired from 250,000 to 500,000 lymphocyte-gated events per sample.  
In order to check intracellular production of IFN-γ, TNF-α and IL-2 cells from lymph 
nodes, samples were stimulated with plate-bound CD3 antibody in the presence of 2 
g/ml of CD28 antibody and 2 g/ml of brefeldin A for 5 h at 370 C. Anti-CD28 was 
used to obtain the full range of T-cell activity in challenged mice. The cells were then 
stained for surface expression of different markers, fixed and permeabilized with 
Cytofix/Cytoperm solution (BD). The cells were then washed, permeabilized, and 
incubated with Fc blocking anti-mouse CD16/CD32. After that cells were labelled with 
monoclonal antibodies specific for IL-2, IFN-γ, TNF-α and anti-CD154. Foxp3, 
Eomes, T-bet expression as well as granzyme B production was detected by 
intranuclear, intracellular staining using an anti-mouse/rat Foxp3 antibody and the 
Foxp3 staining kit. Helios expression was measured by intracellular staining using an 
anti-mouse/human Helios antibody and the Foxp3 staining kit.  
After a double rinse in FACS buffer, the cells were re-suspended in a volume of 400 
µl with FACS buffer and analyzed in detail. Data were acquired from 250,000 to 
500,000 lymphocyte-gated events per sample. The fluorescently-stained 
characteristics of the cells were measured on LSRII flow cytometer and evaluated 
with FlowJo software.  
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4.7 Tetramer and tetramer staining  
Tetramer staining is a gold-standard method for T cell analyses and isolation of a 
very small number of antigen-specific cells. This method established in 1996 by a 
group of scientists Davis, McHeyzer-Williams and Altman was mainly considered to 
label T cells in an antigen-specific manner. Schumacher´s laboratory in Holland 
developed mouse (I-Ab) MHC class II tetramers in which the MHC heterodimers are 
expressed with a genetically fused peptide in insect cells. Heterodimers of the 
extracellular domains of the MHC class II alpha and beta chain are produced in 
insect cells associated with the T cell epitope attached to the beta chain. Four 
identical biotin-containing pMHC complexes are bounded to fluorescently labelled 
streptavidin for binding to TCRs (Fig 4.7). Tetramers bind to T cells that express T 
cell receptors specific for the cognate peptide – MHC complex and can then be 
utilized to track Ag-specific T cells by flow cytometry. MHC–II tetramer positive cells 
are effector CD4+ T cell populations. 
The (I-Ab) class-II tetramers were used to detect the I-Ab FV envelope specific CD4+ 
T cells. 1 x 106 nucleated lymph node cells were incubated with APC-labelled I-Ab 
tetramers for 2-3 hrs at 370C and later stained with surface molecules to quantify the 
population of tumor-specific CD4+ T cells by flow cytometry. After washing, cells were 
stained with anti-CD4 antibody and anti-monocytes CD11b for 8 minutes at 40C. 
Cells were washed, re-suspended in buffer containing PI and analyzed by Flow 
cytometry and 200,000 to 500,000 lymphocyte gated events per sample and analysis 
were recorded.  
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(60) 
4.8 In vivo cytotoxicity assay 
This assay allows determining the cytotoxic function of T cells in different groups of 
tumor-bearing mice (Fig. 4.6). Lymphocytes were isolated from lymph nodes and 
spleens from CD45.1 mice (donor mice), which were depleted for CD4+ and CD8+ T 
cells two times before being sacrificed. This depletion allowed to enrich MHCII+ cells 
by exclusion of all T cells, as only MHCII+ cells can serve as targets for CD4+ T cell-
mediated killing. Single cell suspensions were prepared and the cells were washed 
with 40 ml of PBS. Mononuclear cells from the spleens were separated additionally 
by Percoll density gradient centrifugation. Splenocytes were suspended in 20 ml of 
RPMI 1640 medium and slowly overlaid on a 20 ml Percoll layer in 50 ml Falcon 
tube. After centrifugation (300×g, 10 min, without break) the lymphocytes containing 
middle layer were transferred to the fresh tube. Consequently, cells were washed 
twice in 50 ml of PBS. Cell suspensions from lymph nodes and Percoll-separated 
spleen cells were mixed and divided into equal volumes of 15 ml of RPMI medium 
into two tubes. The cells from one tube were loaded with the class II-restricted 
peptide recognized by CD4+ T cells for 1,5 h at 37°C and afterwards were stained 
with 40nM CFSE (carboxyfluorescein succinimidyl ester) dye for 10 min at 37°C and 
then for 5 min on ice (target cells, experimental). The phenotype of these cells would 
be CD45.1+CFSE+. The unloaded cells remained intact and would be separated from 
the target cells as CD45.1+CFSE- (control cells). Peptide loaded and unloaded cells 
Figure 4.6: Schematic representation of MHC class-II tetramer components 
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were counted using Trypan blue exclusion microscopy and suspended in sterile PBS 
in the ratio 1:1. 1.0×107 cells of each population (per mouse) were injected 
intravenously (i.v.) into tumor-bearing mice. 20 hrs after i.v. injection of the donor 
cells, recipient mice were sacrificed and surface staining with CD45.1 antibody of the 
cells from drLNs was performed. Subsequently, in vivo killing activity was quantified 
in single-cell suspensions from the drLN of each tumor-bearing mouse. 
 
 
 
Figure 4.7: Scheme of the in vivo cytotoxicity assay to show the killing of 
peptide-loaded cells by CD4+ CTL in draining lymph nodes 
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Cytotoxicity was calculated using the following formula: cytotoxicity = 100% × (1- 
((unloaded/loaded)control / (unloaded/loaded)experimental)). 
 
Tumor target lysis assay was performed using 2 ˣ105 FBL-3 cells per mouse labeled 
with 10 μM of CFSE. FBL-3 cells were injected i.p. into naïve CD45.1 mice. 
Additionally, mice received sorted CD4+GFP+ cells from either αCD8, or 
αCD8+αCD137 tumor-bearing or naïve mice. The mice were sacrificed 48 hrs later 
and intraperitoneal lavage was performed with 10 ml PBS to obtain cells. Cells were 
washed once, re-suspended in buffer containing fixable viability dye to exclude dead 
cells and analyzed by flow cytometry for CFSE+ signal. 
4.9 Cell isolation with the MACS technology 
MACS technology is a fast method for the isolation of viable and functionally active 
cells by magnetic labeling. It is grounded on MACS MicroBeads in combination with 
manual MACS separators and columns. When MACS columns are placed in MACS 
separator, the MACS columns matrix provides a magnetic field strong to retain cells 
labelled with the magnetic beads. The magnetically labelled cells are retained in the 
column, while unlabeled cells pass through. The retained cells are eluted from the 
MACS column after removal from the magnet. 
The isolation of CD4+ T cells was conducted using the mouse CD4+ T cell isolation kit 
II, which provides only labeling of non-CD4+ T cells. With this negative isolation the 
pre-activation of CD4+ T cells is prevented. Briefly, the cells were re-suspended in 
MACS buffer (40μL buffer per 1x107 cells). Afterwards biotinylated antibody cocktail 
was added to couple all non-CD4+ T cells (10μL buffer per 1x107 cells). The cell 
suspension with the biotinylated antibody cocktail was incubated for 10 minutes at 
4°C in the dark. Ten minutes later Macs buffer was added (30μL buffer per 1x107 
cells). Then anti-biotin magnetic Microbeads were added (20μL buffer per 1x107 
cells). After the incubation period of 20 minutes cells were washed by the 
centrifugation for 10 minutes at 520 xg. Next, supernatant was discarded and cells 
were re-suspended in 700μL MACS buffer per 1x107 cells. The LS columns were 
equilibrated in the magnetic field of the MACS separator. LS columns were washed 
with MACS buffer three times before being used. Each sample was passed through 
the magnetic columns and un-labeled CD4+ cell population was collected in the 
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separate tubes. Collected cells were centrifuged and the pellets are re-suspended 
with 1 ml PBS.  
FACS analysis of the 10.000 cells was always performed for proving the CD4+ T cell 
purity. 
4.10 Sorting of GFP+ Tregs and adoptive cell transfer  
A fluorescence-activated cell sorter is used to retrieve populations of interest from a 
heterogeneous population for further study. If a cell can be specifically identified by 
its physical or chemical characteristics, it can be separated using a flow sorter. 
Briefly, when the specific cells pass through a laser beam they are monitored. 
Droplets containing single cells are given a positive or negative charge, based on 
whether the cell has limited the fluorescence or not. Droplets containing a single cell 
are then detected by an electric field into collection tubes according to their charge 
For the transfer experiments of GFP+ CD4+ T cells, pre-enriched CD4+ T cells (MACS 
technology) from DEREG mice were sorted on the basis of GFP fluorescence. 
Separation of the GFP+CD4+ from GFP-CD4+ T cells was performed on a FACSDiVa 
cell-sorter (Becton Dickinson, San Jose, CA). GFP was excited with a 488 nm laser 
wavelength and fluorescence was measured through a 585/42 nm bandpass filter. 
For each experiment 200.000–330.000 cells were sorted by flow cytometry. 
After the separation of the cells the purity of the separated cell populations was 
always analyzed again by flow cytometric analysis of 10.000 cells. To >95% pure 
populations of CD4+GFP+ or CD4+GFP-cells was achieved. 
Between 1 and 3 x106 CD4+GFP- cells and 1-5 x105 CD4+GFP+ cells were transferred 
into CD45.1 recipients by i.v. injection in 0.5 ml PBS on day 0 following FBL-3 
challenge and antibodies administration.  
4.11 Exclusion of dead cells in flow cytometry 
The exclusion of dead cells and cellular debris in flow cytometry was performed using 
the dye propidium jodide (PI). PI has a high DNA binding constant and is efficiently 
excluded by intact cells. It is useful for DNA analysis and dead cell discrimination 
during flow cytometric analysis. When excited by 488nm laser light, PI fluorescence 
is detected in the far red range of the spectrum (562-588nm band-pass filter). In 
healthy cells, the intact cell membrane prevents the fast access of PI and therefore it 
is only slowly absorbed by the healthy cells. However, should a cell be apoptotic or is 
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damaged or killed in the measuring process, then the cell membrane lacks its 
protective function and PI rapidly diffuses into the cell. There, it is taken up in the cell 
nucleus and DNA with which it interacts. The cell is thus marked as “dead” and can 
be detected by the flow cytometer. PI in amount of 1 µl was added to the stained 
cells in 400 µl FACS buffer and the sample was immediately analysed.  
For the exclusion of dead cells in intracellular staining, Fixable Viability Dye (FVD) 
was used. FVD is a viability dye that can be used to label dead cells prior to fixation 
and/or permeabilization procedures. FVD stain is based on the reaction of a 
fluorescent reactive dye with cellular proteins (amines). These dyes cannot penetrate 
live cell membranes, so only cell surface proteins are available to react with the dye, 
resulting in dim staining. The reactive dye can infuse the damaged membranes of 
dead cells and stain both the interior and exterior amines, resulting more intense 
staining. FVD eF780 was added in amount of 1 µl per 1 mL of cells together with the 
surface staining antibodies.  
4.12 Statistical analyses 
Statistical analyses and graphical presentations were computed with Graph Pad 
Prism version 5. Statistical differences (p-value) between two groups were performed 
using unpaired t test. Statistical differences (p-value) between the different 
parameters were performed testing with the Kruskal-Wallis one-way analysis of 
variance on ranks and Newman-Keuls multiple comparison tests. The p-value is a 
probability with a value ranging from zero to one. In this work, all p-values ≤ 0.05 
were determined significant. 
 
RESULTS 
50 
5  RESULTS 
Despite of robust tumor immunity, tumor growth is not controlled in cancer patients. 
Consequently, this can lead to metastasis and death. One approach of cancer 
immunotherapy in the animal model has been the stimulation of the Tumor Necrosis 
Factor Receptor (TNFR) superfamily member CD137 (also known as 4-1BB), which 
is involved in T cell activation and function (122) including expansion, survival, and 
cytokine production of effector T cells (27, 73). This work set out to investigate the 
effector function of CD4+ T cells and Tregs in the course of CD137 co-stimulation 
during virus-induced tumor formation. 
The experiments described in the current work were performed with C57BL/6 (B6) 
mice. The tumor size was measured and the role of different immune cell subsets 
was identified. As lymph nodes play a central role in anti-tumor immunity, our main 
focus in the FBL-3 model was on tumor draining lymph nodes (drLN). FBL-3 cells 
(1×107) were injected into the right flank of B6 mice and after 6 days post tumor 
challenge (ptc), T cell responses were determined. 
5.1 CD137 agonist therapy in CD8+ T cell depleted mice promotes FBL-3 
tumor cell rejection through a CD4-dependent mechanism 
T cell immune responses against tumor cells play a pivotal role in the arrest of tumor 
growth. Prior studies have shown that CD8+ T cells are essential in controlling FBL-3 
tumor progression (64, 153). As others have seen in this model, we observed no 
tumor control in mice depleted for CD8+ T cells and animals had to be euthanized in 
average 15 days after tumor infusion (Fig. 5.1B). To define the influence of a co-
stimulatory CD137 antibody on the CD4+ T cell compartment in tumor protection, 
CD8+ T cell depleted tumor-bearing mice were treated every second day with the 
CD137 antibody starting at day 0 (described in Methods). Strikingly, despite the 
absence of CD8+ T cells, the co-stimulation of CD4+ T cells with CD137 agonist 
restored anti-FBL-3 tumor immunity and injected FBL-3 cells were completely 
rejected after in average 22 days of tumor challenge (Fig. 5.1C). This is only a slight 
delay of 7 days in tumor rejection compared to only FBL-3 challenged mice, in which 
CD8+ T cells mediate tumor rejection (Fig. 5.1A). This experiment suggests that even 
in the absence of the cytotoxic CD8+ T cell compartment CD4+ T cells are capable of 
controlling tumor progression. In order to prove that tumor rejection was due to a 
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αCD137 induced effector CD4+ T cell responses, tumor growth was analyzed in mice 
lacking both CD4+ and CD8+ T cells, and administrated with a αCD137 antibody. 
Additional depletion of CD4+ T cells reversed the effects on tumor rejection - in the 
absence of these T cell compartments no control of tumor growth was observed (Fig. 
5.1D), indicating that CD4+ T cells can mediate anti-tumor immunity when stimulated 
with CD137 antibody. 
 
Figure 5.1: Influence of different cell populations and αCD137 therapy on tumor 
formation 
Effects of depletion of CD8+ T cells (B), depletion of CD8+ T cells and αCD137  treatment (C), 
depletion of CD8+ T cells, CD4+ T cells and αCD137  treatment (D). A, no depletion (injected 
with PBS). B6 mice were injected s.c. with 1×107 FBL-3 cells (1×107) and tumor size was 
measured. Mice were depleted for their CD8+, CD4+ T cells as described in methods. Each 
line represents tumor progression in an individual mouse. Dragger symbol: mice were 
euthanized due to progressive tumor growth. 
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5.2 CD137 ligation increases the numbers of activated tumor-specific 
CD4+ T cells in draining lymph nodes of FBL-3 challenged mice 
To understand the underlying immunbiology of the described phenomenon, we next 
characterized differences in the anti-tumor CD4+ T cell responses in mice depleted 
for CD8+ T cells compared to those that also received CD137 agonist treatment 
during FBL-3 tumor challenge. The total population of CD4+ T cells showed no 
differences in numbers between the groups only lacking CD8+ T cells and additionally 
treated with αCD137 (Fig. 5.2).  
 
Figure 5.2: αCD137 therapy leads to the expansion of CD4+ T cells in draining 
lymph nodes 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and depleted for CD8+ T cells. 
Simultaneously with tumor inoculation, some mice also received αCD137 treatment as 
described in methods. At day 6 post tumor challenge (ptc) draining lymph nodes were 
analyzed for total numbers of CD4+ T cells by flow cytometry. The experiment was repeated 
three times with comparable results. 
 
However, the expression of the proliferation-associated antigen Ki67 on CD4+ T cells 
from draining lymph nodes was significantly enhanced in mice treated with CD137 
agonist antibody and depleted for CD8+ T cells in comparison to mice only lacking 
CD8+ T cells or in naïve animals (Fig. 5.3A). One possible explanation for the 
unaltered CD4+ T cell numbers despite increased cell proliferation was that these 
cells might leave the drLN and migrate into the tumor microenvironment. It has 
previously been demonstrated that in FBL-3 tumor challenged mice CD4+ T cells 
infiltrate the tumor bed and constitute a significant part of the tumor infiltrating 
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lymphocytes (2). In addition, we analyzed expression of KLRG-1 (killer cell lectin-like 
receptor subfamily G member 1, a marker for terminally differentiated effector T cells) 
(56) on CD4+ cells from different groups of mice. Significantly higher proportions of 
CD4+ T cells expressed KLRG-1in mice following co-stimulatory therapy than in the 
control groups (Fig. 5.3B).  
 
Figure 5.3: αCD137 therapy leads to the activation of CD4+ T cells in draining 
lymph nodes 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and additionally treated with αCD8. 
Some mice also received αCD137 treatment as described in methods. At day 6 ptc draining 
lymph nodes were analyzed for expression of different molecules by flow cytometry. A, the 
maturation profile was detected by surface expression of KLRG-1. B, the proliferation of 
CD4+ T cells was measured by the intracellular expression of Ki67. Each dot represents an 
individual mouse and the mean numbers are indicated by a line. Differences between the two 
groups were analyzed by using one-way ANOVA test. Statistically significant differences 
between the groups are given in the figures (***P˂0.0005). The experiment was repeated 
three times with comparable results. 
 
Next, we focused on the specific characteristics of CD4+ T cells in mice depleted for 
CD8+ T cells following CD137 therapy. Significantly enhanced numbers of CD4+ T 
cells co-expressed the activation markers CD43 (the activation-induced glycosylated 
isoform) (69) and CD11a (a co-stimulatory signaling molecule upregulated upon 
antigen recognition) (90) in mice following CD137 therapy and CD8+ T cell depletion 
than in mice only depleted for CD8+ T cells or in naïve animals (Fig. 5.4A). It has 
been shown that FBL-3 tumor cells expresses FV antigens that can be recognized by 
CD8+ and CD4+ T cells (18, 63). To analyze the tumor-specific immune response 
after CD137 treatment we used the tetramer technology (as described in Materials 
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and Methods) to stain lymphocytes from the drLN of FBL-3 challenged mice with 
MHC class-II tetramers loaded with the I-Ab-restricted MoMSV-envelope epitope 
(H19-Env) peptide-encoding (EPLTSLTPRCNTAWNRLKL) sequence (115). At 6 
days ptc αCD137-treated mice had significantly more tetramer+ CD4+ T cells than 
only CD8+ T cell depleted mice that did not receive treatment (Fig. 5.4B) showing that 
αCD137 signaling enhances tumor-specific CD4+ T cell immunity. These data 
demonstrate that targeting the CD137 molecule with an agonist antibody in tumor-
bearing mice depleted for CD8+ T cells leads to the expansion of activated and highly 
differentiated tumor-specific CD4+ T cells. 
 
Figure 5.4: αCD137 therapy leads to the activation of CD4+ T cells in draining 
lymph nodes 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and additionally treated with αCD8. 
Some mice also received αCD137 treatment as described in methods. At day 6 ptc draining 
lymph nodes were analyzed for expression of different molecules by flow cytometry. B, the 
activation of CD4+ T cells was analyzed by surface expression of CD11a and CD43 (double 
positive). Numbers of leukemia specific CD4+TetII+ T cells reactive with I-Ab MHC class-II 
tetramers specific for the FV-Env epitope (B). All tetramer positive T cells expressed cell-
surface activation marker CD43 and CD11a. Each dot represents an individual mouse and 
the mean numbers are indicated by a line. Differences between the two groups were 
analyzed by using one-way ANOVA test. Statistically significant differences between the 
groups are given in the figures (**P˂0.005, ***P˂0.0005). The experiment was repeated five 
times with comparable results. 
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5.3 αCD137 therapy leads to expansion of activated CD4+ T cells with T 
helper phenotype 
To test whether the anti-tumor effect following CD137 therapy was driven by 
improved CD4+ T helper cell activity, we performed functional studies of FBL-3-
induced CD4+ T cells by analyzing T-box transcription factor (T-bet) (109) expression 
as well as production of the key pro-inflammatory cytokines IFN-γ, TNF-α and IL-2. 
To characterize the total population of CD4+ T helper cells that was activated during 
tumor growth and rejection, we used the marker CD154 (CD40L) (17). In order to 
exclude Tregs from the conventional CD4+ T helper cells (Tcon) we also stained for 
intracellular expression of the transcriptional factor forkhead box P3 (Foxp3). 
Following CD137 agonist therapy in tumor-bearing CD8+ T cells-depleted mice, we 
observed a significantly enhanced number of T-bet expressing conventional CD4+ T 
cells than in the groups only depleted for CD8+ T cells or naïve mice (Fig. 5.5A). 
However, there was no significant increase of CD154 expression in CD137 agonist 
treated mice in comparison to only CD8+ T cell-depleted animals (Fig. 5.5B).  
 
 
Figure 5.5: αCD137 ligation results in functional reactivation of CD4+ T cells in 
draining lymph nodes of tumor bearing mice 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and additionally treated with αCD8. 
Some mice also received αCD137 treatment as described in methods. At day 6 ptc draining 
lymph nodes were analyzed for expression of different molecules by flow cytometry. 
Intracellular marker Foxp3 was used to exclude Treg cell population from the analysis. (A) 
Flow cytometry was used to determine the numbers of CD4+ T cells expressing intracellular 
transcription factor T-bet (A). Numbers of activated (positive for CD154) CD4+Foxp3- T cells 
(B) in different treatment of mice. Differences between the two groups were analyzed by 
using one-way ANOVA test. Statistically significant differences between the groups are given 
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in the figures (*P˂0.05, **P˂0.005, n.s. – not significant). The experiments were repeated at 
least five times with comparable results. 
 
CD154 is a marker of activation, which is transiently expressed on the surface of 
CD4+ T cells activated through ligation of their T-cell receptor. Tumor-bearing mice 
depleted for CD8+ T cells show an activated phenotype of CD4+ T cells by CD154 
expression, although tumor control was abolished (Fig. 5.1B). In this group CD154+ T 
cells were weak producers of pro-inflammatory cytokines. Using intracellular cytokine 
staining after stimulation with αCD137, we found significantly more CD4+CD154+ T 
cells producing the cytokines IFN-γ, TNF-α and IL-2 (Fig. 5.6). Notably, while CD154 
expression was significantly increased in CD8+ T cell deficient animals, the frequency 
of CD4+CD154+ T cells producing one of the three cytokines was not improved in the 
same group compared to the naïve control mice. Collectively, the data indicates that 
in the absence of CD8+ T cells αCD137 therapy induces strong CD4+ T cell 
responses with T helper phenotypes in the FBL-3 tumor model. 
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Figure 5.6: αCD137 ligation results in improved production of cytokines in 
CD4+ T cells from draining lymph nodes of tumor bearing mice 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and additionally treated with αCD8. 
Some mice also received αCD137 treatment as described in methods. At day 6 post tumor 
transplantation lymphocytes from draining lymph nodes were analyzed. Intracellular marker 
Foxp3 was used to exclude Treg cell population from the analysis. Frequencies of 
CD4+CD154+ T cells producing cytokines (IFN-γ, TNF-α and IL-2) are shown (A-C). 
Differences between the two groups were analyzed by using one-way ANOVA test. 
Statistically significant differences between the groups are given in the figures (**P˂0.005, 
***P˂0.0005). The experiments were repeated at least three times with comparable results. 
 
5.4 αCD137 treatment induces tumor-specific cytotoxic CD4+ T cells that 
can kill FBL-3 cells 
It has been demonstrated that after αCD137 therapy T-box transcription factor 
Eomesodermin (Eomes) mediates the expression of cytotoxicity-associated genes 
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that are efficient in killing tumor cells (28). Interestingly, the CD4 T cells in CD8-
depleted, αCD137-treated mice showed significantly enhanced expression of Eomes 
(Fig. 5.7A). CD4+ T cells usually express only little Eomes as cytotoxicity is mostly 
mediated by CD8+ T cells, suggesting that CD4+ T cells may have acquired cytotoxic 
activity after CD137 signaling. Additionally, significantly higher numbers of CD4+ T 
cells from αCD137-treated mice produced the lytic molecule granzyme B (Fig. 5.7B), 
which is known to be important for controlling cancer (25). Indeed, we found that 
Eomes+CD4+ T cells from the treated mice showed substantially higher expression of 
the effector molecule granzyme B (Fig. 5.8). Nine percent of all conCD4+ T cells were 
double positive for Eomes and granzyme after αCD137 treatment (Fig. 5.8A), which 
corresponded to 36% of the Eomes+CD4+ T cells producing granzyme B (Fig. 5.8B). 
The induction of tumor-specific CD4+ T cells expressing granzyme B suggested that 
these cells might be responsible for the tumor elimination in αCD137-treated, CD8+ T 
cell depleted mice (Fig. 5.1C). 
 
Figure 5.7: αCD137 + αCD8 combination therapy programs cytotoxic CD4+ T 
cell differentiation 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and additionally treated with αCD8. 
Some mice also received αCD137 treatment as described in methods. At day 6 ptc 
CD4+Foxp3- (conCD4+) T cells from draining lymph nodes were analyzed. A, intracellular 
expression of transcription factor Eomesodermin (Eomes) was measured by flow cytometry 
and numbers of Eomes+ conCD4+ T cells from mice of the different groups are shown. B, 
numbers of CD4+Foxp3- T cells producing granzyme B (GzmB). Each dot represents an 
individual mouse and the mean percentages are indicated by a line. Differences between the 
two groups were analyzed by using one-way ANOVA test. Statistically significant differences 
between the groups are given in the figures (**P˂0.005, ***P˂0.0005). All experiments were 
repeated at least three times with comparable results. 
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B6 mice were inoculated s.c. with 1×107 FBL-3 cells on day 0. Simultaneously with tumor 
inoculation, mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 
(described in methods). At day 6 post tumor transplantation CD4+Foxp3- (conCD4+) T cells 
from draining lymph nodes were analyzed. A, representative dot plot of Eomes and GzmB 
expression (A) from mice of the different groups. B, representative contour plot of GzmB 
producing conCD4+Eomes+ T cells in different treatment of mice. Data are representative for 
at least 3 independent experiments. 
 
To analyze whether the increased expression of the cytotoxic molecule granzyme B 
correlated with improved tumor specific lysis of target cells following CD137 agonist 
therapy we performed a series of in vivo killing experiments. Tumor-bearing mice 
were depleted for CD8+ T cells with or without additional αCD137 treatment. Five 
days after tumor challenge all groups of mice received lymphocytes from naïve 
CD45.1 donor mice that were loaded with a MHC class II-restricted FBL-3-specific 
CD4+ T cell epitope peptide (115). These donor lymphocytes served as CFSE-
labeled targets. Twenty hours after i.v. injection of CFSE targets (day 6 ptc), mice 
Figure 5.8: αCD137 + αCD8 combination therapy leads to the expansion of 
granzyme B producing CD4+ T cells 
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were sacrificed and in vivo killing activity was quantified in single-cell suspensions 
from the drLN of each tumor-bearing mouse. The in vivo cytotoxicity assay revealed 
that CD4+ T cell killing was at the detection limit of the assay in only CD8+ T cell 
depleted tumor-bearing mice, whereas the additional αCD137 treatment resulted in 
an average of more than 30% target cell killing (Fig. 5.9). Moreover, when peptide-
loaded targets from MHCII-/- mice were used in the assay, we found that all killing 
activity of effector CD4+ T cells was lost, confirming the specific TCR-MHC-II 
recognition in CD4+ T cell depended killing. Collectively, these data suggest that 
tumor-specific CD4+ T cells can gain cytotoxic activity against FBL-3 tumor cells 
when CD8+ T cells are not active but this activity is dependent on co-stimulatory 
signals of the CD137 pathway.  
 
Figure 5.9: αCD137 + αCD8 combination therapy leads to CD4+ T cell killing 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells on day 0. Simultaneously with tumor 
inoculation, mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 
(described in methods). Mean percentages of killing in vivo CTL assay. Briefly, tumor bearing 
mice were depleted for their CD8+ T cells and treated or not with αCD137. Target cells from 
the spleen and lymph nodes of the naive donor mice were labeled with CFSE and pulsed 
with the specific CD4 epitope peptide. Another cell population was obtained from naïve 
CD45.1 mice and not pulsed with peptide. In order to verify tumor-specific killing, cells from 
MHCII-/- were used as donor cells and labeled either with CFSE or with CellTrace Violet. At 
day 5 after tumor inoculation, both populations of target cells were co transferred 
intravenously into treated tumor-bearing mice. Cells from MHCII-/- mice were only 
transferred into mice treated with αCD8 + αCD137. Twenty hours later, lymphocytes were 
isolated from the draining lymph nodes and analyzed by flow cytometry to determine the 
percentage of remaining target cells that are either CFSE+,CD45.1+ or CellTrace Violet+. 
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Each dot represents an individual mouse and the mean percentages are indicated by a line. 
Differences between the two groups were analyzed by using one-way ANOVA test. 
Statistically significant differences between the groups are given in the figures (***P˂0.0005). 
All experiments were repeated at least three times with comparable results. 
5.5 αCD137 therapy leads to expansion of Tregs 
We have previously shown that direct anti-tumor effects of CD4+ T cells were strictly 
regulated by Tregs (2). In the absence of CD8+ T cells Tregs suppressed effector 
CD4+ T cell responses and impaired tumor rejection (Fig. 5.10) (2). 
DEREG mice were injected s.c. with 1×107 FBL-3 cells (1×107) and tumor size was 
measured. Mice were depleted for their Tregs and CD8+ T cells as described in methods. 
Each line represents tumor progression in an individual mouse.  
 
As we found that αCD137 treatment drives CD4+ T cell mediated cytotoxicity and 
restores anti-tumor immunity as described above, we next investigated whether 
αCD137-treatment influences the otherwise suppressive response of Tregs. We first 
confirmed expression of CD137 on Tregs of FBL-3 challenged mice and found 
indeed expression of CD137 on Tregs (Fig. 5.11). A subpopulation of Tregs 
expressed the CD137 molecule on a subpopulation of activated (CD43+) Tregs in 
FBL-3 challenged mice and therefore might be possible consumers of CD137 
antibodies (Fig. 5.11). 
Figure 5.10: Influence of both CD8+ T cell and Treg depletion on tumor 
formation 
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Figure 5.11: Expression of CD137 on Tregs from draining lymph nodes of 
tumor bearing mice 
DEREG mice were inoculated s.c. with 1×107 FBL-3 cells on day 0. At day 6 ptc GFP+ T cells 
from draining lymph nodes were analyzed. Representative dot plot of CD137 and CD43 
expression in naïve and tumor-bearing DEREG mice are shown. Data are representative for 
at least 3 independent experiments. 
 
It was of interest to investigate the impact of CD137 agonist on the phenotype and 
function of Tregs during FBL-3 tumor rejection. On day 6 ptc Tregs migrate from 
lymph nodes to the tumor microenvironment in FBL-3 tumor-bearing mice and in 
drLNs constitute only 13% of the total CD4+ T cell population (2). In contrast, 
following αCD137 injection mice lacking CD8+ T cells and challenged with tumor 
showed a significant expansion of Foxp3+ Tregs comprising up to 30% of all CD4+ T 
cells in the tumor-draining lymph nodes (Fig. 5.12A). 
CD25 expression by CD4+ T cells is widely used as a marker to identify Tregs. 
However, cells with regulatory properties are also found in the CD4+CD25- subset. 
We therefore assayed which subpopulation of Foxp3+ Tregs (CD25+ or CD25-) was 
expanded after the agonist CD137 immunotherapy. Interestingly, no enhancement in 
CD25- Treg numbers was observed in the group of mice treated with αCD137 in 
comparison to the control groups (Fig. 5.12B). In contrast, a significant increase in 
numbers of Foxp3+CD25+ cells was detected in αCD137 treated mice compared to 
animals only depleted for CD8+ T cells and challenged with FBL-3 tumor cells (Fig. 
5.12B). 
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Figure 5.12: αCD137 stimulates expansion of CD25+ Tregs 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor inoculation, 
mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 (described in 
methods). At day 6 ptc draining lymph nodes were analyzed for total numbers of CD4+ 
Foxp3+T cells (A). B, numbers of CD25- and CD25+ in Foxp3+ T cells. Differences of groups 
are presented in bars and means are indicated by a line. Differences between the two groups 
were analyzed by using one-way ANOVA test. Statistically significant differences between 
the groups are given in the figures (***P˂0.0005, n.s. – not significant). The experiment was 
repeated at least five times with comparable results. 
 
5.6 CD137 signaling elicits activation, proliferation, and differentiation 
of nTregs 
Next, we investigate the impact of CD137 agonist on the phenotype and function of 
Tregs during FBL-3 tumor rejection. The αCD137 treatment induced significant 
activation and differentiation of Tregs, as indicated by expression of the markers 
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(CD43 and CD11a (Fig. 5.13A, (68)). Significant improvement of these molecules 
expression by CD4+Foxp3+ T cells was observed in αCD137 treated mice and 
depleted for CD8+ T cells than in control groups of only depleted and naïve animals 
(Fig. 5.13A). The same trend was discernible for tumor-specific tetramerII+ regulatory 
T cells, although it failed to reach statistical significance (Fig. 5.13B).  
 
Figure 5.13: αCD137 stimulates Tregs activation 
DEREG mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor 
inoculation, mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 
(described in methods). At day 6 ptc draining lymph nodes were analyzed for expression of 
different molecules by flow cytometry. A, Total numbers of surface expression of CD11a and 
CD43 (double positive). Numbers of leukemia specific CD4+GFP+TetII+ T cells reactive with I-
Ab MHC class-II tetramers specific for FV-Env epitope (B). All tetramer positive T cells 
expressed cell-surface activation marker CD11a. Each dot represents an individual mouse 
and the mean numbers are indicated by a line. Differences between the two groups were 
analyzed by using one-way ANOVA test. Statistically significant differences between the 
groups are given in the figures (***P˂0.0005, n.s. – not significant). The experiment was 
repeated three times with comparable results. 
 
We also found a significant increase of recently proliferated Tregs identified by the 
expression of Ki67 (Fig. 5.14A), which goes in line with the previous findings of the 
expanded Treg population, comprising up to 30% of all CD4+ T cells in the tumor-
draining lymph nodes (Fig. 5.12A). Furthermore, we observed an increased 
expression of the maturation marker KLRG-1 on Tregs, which have been linked to 
cytotoxic activity of CD8+ T cells and NK cells (Fig. 5.14B). 
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Figure 5.14: αCD137 stimulates Tregs proliferation and differentiation 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor inoculation, 
mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 (described in 
methods). At day 6 ptc draining lymph nodes were analyzed for expression of different 
molecules on Foxp3+CD4+ T cells by flow cytometry. A, the proliferation of CD4+ T cells was 
measured by the intracellular expression of Ki67. B, the maturation profile was detected by 
surface expression of KLRG-1. Each dot represents an individual mouse and the mean 
numbers are indicated by a line. Differences between the two groups were analyzed by using 
one-way ANOVA test. Statistically significant differences between the groups are given in the 
figures (**P˂0.005, ***P˂0.0005). The experiment was repeated three times with comparable 
results. 
 
Next, it was of interest to determine the origin of Tregs. Tregs can derive from thymus 
(nTregs) or come from peripherally, induced iTregs. Firstly, Helios was known as a 
marker of nTregs (127), however recently it was mostly used as marker for Treg 
activation (3). Neuropilin 1 (Nrp-1), a receptor for ligands of the vascular endothelial 
growth factor family was identified as a marker for nTregs (12). Interestingly, the vast 
majority of Tregs expanding after CD137 treatment expressed Nrp-1 (Fig. 5.15A), 
suggesting that CD137 treatment mostly affected thymic-derived nTregs. This was 
also supported by the observation that Foxp3+ Tregs expanded in the thymus of 
αCD8+αCD137 treated tumor-bearing mice (Fig. 5.15B). Thus, αCD137 treatment of 
CD8 depleted, tumor bearing mice induced strong activation, proliferation, and 
differentiation of a subset of nTregs. 
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Figure 5.15: Expansion of natural Tregs in the draining lymph nodes and in the 
thymus of tumor-bearing mice following CD137 agonist therapy 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor inoculation, 
mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 (described in 
methods). At day 6 ptc draining lymph nodes and thymus were analyzed by flow cytometry. 
Numbers of Treg cells in draining lymph nodes analyzed for expression of surface 
Neuropilin1 (Nrp1) in differently treated tumor-bearing mice (A). B, total numbers of 
CD4+Foxp3+T cells in thymus. Differences between the two groups were analyzed by using 
one-way ANOVA test. Statistically significant differences between the groups are given in the 
figures (*P˂0.05, ***P˂0.0005). The experiment was repeated three times with comparable 
results. 
 
5.7 A subset of Tregs acquires helper and cytotoxic CD4+ T cell 
functions after αCD137 treatment 
The CD137 agonist antibody augmented Treg responses in tumor bearing mice but 
this activation did not result in suppression of anti-tumor immunity. We therefore 
asked, whether αCD137 activated Tregs showed evidence of phenotypic plasticity 
and acquired anti-tumor effector functions. We examined the in vivo induction of 
CD154 expression, a functional mediator of T cell help (CD40-ligand) (116), on Tregs 
in drLNs of αCD137 treated mice. Figure 5.16A shows that CD154 was expressed on 
a subset of Foxp3+ Tregs after treatment. To investigate the functionality of these 
cells, the expression of proinflammatory cytokines (IL-2, IFN-γ, TNF-α) was 
measured. The production of these cytokines implies a major alteration in the Treg 
phenotype, because they are strongly suppressed in the Foxp3+ lineage (147). While 
CD8+ T cell deletion induced no TNF-α production in CD4+Foxp3+ from tumor drLNs, 
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an addition of αCD137 mediated TNF-α production in the subset of CD154/Foxp3 
double-positive cells (Fig. 5.16B). Remarkably, these CD4+ T cells only produced 
TNF-α but not IL-2 or IFN-γ (data not shown).  
 
Figure 5.16: Tregs upregulate helper T cell markers after αCD137 treatment 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor inoculation, 
mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 (described in 
methods). At day 6 ptc Foxp3+ Treg cells from draining lymph nodes were analyzed for 
different characteristics. A, numbers of Foxp3+ T cells expressing CD154 molecule. C, 
CD154+Foxp3+ T cells producing TNF-α. Differences between the two groups were analyzed 
by using one-way ANOVA test. Statistically significant differences between the groups are 
given in the figures (**P˂0.005, ***P˂0.0005). The experiment was repeated three times with 
comparable results. 
 
To determine if αCD137 therapy also induced markers of cytotoxicity in Foxp3+CD4+ 
T cells from FBL-3 challenged mice, we quantified the expression of the T-box 
transcriptional factor Eomes in these cells, which strongly correlates with T cell 
cytotoxicity. Strikingly, the number of Eomes expressing Foxp3+ T cells was 
significantly increased in αCD137 treated mice compared to animals only depleted 
for CD8+ T cells and challenged with FBL-3 tumor cells (Fig. 5.17A). Only in the 
presence of αCD137 the Treg cell fraction supported Eomes upregulation, 
comprising up to 3% of total CD4+ T cells in contrast to non-treated αCD8 received 
mice (0,1%) or naïve animal (0,1%) (Fig. 5.17B). 
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Figure 5.17: Tregs acquire an effector-like phenotype following αCD137 therapy 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor inoculation, 
mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 (described in 
methods). At day 6 ptc Foxp3+ T cells from drLNs were analyzed for transcription factor 
Eomes. Numbers of Eomes expressing Treg cells are shown in A. B, representative dot plots 
of Eomes+Foxp3+ Treg cells in different treatment of mice are shown. Differences between 
the two groups were analyzed by using one-way ANOVA test. Statistically significant 
differences between the groups are given in the figures (***P˂0.0005). The experiment was 
repeated three times with comparable results.  
 
Up to 14% of the Foxp3+CD4+ T co-expressed Eomes after αCD137 injection, 
whereas almost none of these double-positive cells were found before antibody 
treatment (Fig. 5.18). Most of the Foxp3+Eomes+CD4+ T cells also expressed the 
Treg activation marker Helios (Fig. 5.18). 
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Figure 5.18: Expression of Eomes in Tregs 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells on day 0. At day 6 ptc Foxp3+ T cells 
from draining lymph nodes were analyzed. Representative dot plots of Eomes and Helios 
expression in different group of mice are shown. Data are representative for at least 3 
independent experiments. 
 
In addition, within the tumor draining lymph nodes Foxp3+CD4+ T cells started to 
produce granzyme B following αCD137 therapy, whereas no granzyme B production 
was found in the cells of mice from the control groups (Fig. 5.19). Taken together, 
these results demonstrate that CD137 signaling may convert subsets of Tregs into 
cytokine expressing helper T cells or even cytotoxic killer cells. 
 
Figure 5.19: CD137 ligation leads to increased GzmB production by Tregs 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells. Simultaneously with tumor inoculation, 
mice also received monoclonal antibody to deplete CD8+ T cells and αCD137 (described in 
methods). The numbers of GzmB producing Treg cells in draining lymph nodes at day 6 ptc 
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are shown. Differences between the two groups were analyzed by using one-way ANOVA 
test. Statistically significant differences between the groups are given in the figures 
(***P˂0.0005). The experiment was repeated three times with comparable results. 
 
5.8 CD137 stimulated Foxp3+ CD4+ T cells mediate tumor cell killing 
The effector cell characteristics found in CD137 stimulated Foxp3+ CD4+ T cells 
prompted us to ask whether these reprogrammed Tregs were capable of eliminating 
FBL-3 tumor cells. We performed a series of in vivo killing experiment in DEREG 
mice, which express a diphtheria toxin (DT) receptor under the control of the Foxp3 
promoter. Intravenous administrations of DT allow to rapidly (within hours) and 
selectively delete more than 95% of Foxp3+CD4+ T cells (Fig. 5.20). 
 
Figure 5.20: Efficacy of Treg depletion in DEREG mice 
DEREG tumor-bearing mice were injected with DT i.v. as described in methods. 
Lymphocytes from drLNs were stained for intracellular Foxp3 production and gated on CD4+ 
T cells. Loss of Tregs (CD4+Foxp3+GFP+ T cells) in a representative DEREG mouse treated 
with DT i.v. is shown. Percentages of CD4+Foxp3+GFP+ T cells (upper and lower right 
quadrant) are given above the dot plots.  
 
This was important because we wanted to study the immediate effect of the Foxp3+ 
cells on target cells and not the secondary effect that a more sustained Treg 
depletion has on effector T cell responses. DEREG mice were challenged with 
tumors, depleted for CD8+ T cells and treated with αCD137 to induce the population 
Foxp3+CD4+ T cells with cytotoxic effector phenotype. Cell tracer-labeled peptide-
loaded (Friend Virus CD4+ T cell epitope peptides that are expressed on FBL-3 tumor 
Non-depleted
G
F
P
Foxp3
Treg-depleted
Treg depletion
DT
7% 0.2%
RESULTS 
71 
cells) target cells were injected intravenously (i.v.) simultaneously with DT or PBS on 
day 5 ptc and the in vivo killing of the targets was determined 20 hrs later. In PBS 
control mice the total population of CD4+ T cells, including conventional T cells and 
the Foxp3+CD4+ T cells that expressed Eomes mediated a potent in vivo killing 
activity (Fig. 5.21). Strikingly, this activity was significantly decreased after specific 
Foxp3 ablation due to DT administration (Fig. 5.21), suggesting a potent contribution 
of the converted Tregs to the total MHC class II restricted killing of peptide-loaded 
targets.  
 
Figure 5.21: Functional plasticity of Tregs after αCD137 treatment leads to FBL-
3 tumor elimination 
Mean percentages of killing in vivo CTL assay (described in methods). FBL-3 tumor bearing 
DEREG mice were depleted for their CD8+ T cells and treated with αCD137. Target cells 
from the spleen and lymph nodes of the naive donor mice were labeled with CFSE and 
pulsed with the specific CD4 epitope peptide to be tested. Additionally naïve cells from 
CD45.1 mice were isolated and not pulsed with peptide. At day 5 after tumor inoculation, 
both populations of target cells together with diphtheria toxin (DT) were co transferred 
intravenously in the same amount into treated DEREG tumor-bearing mice. Twenty hrs later, 
lymphocytes were isolated from the draining lymph nodes and analyzed by flow cytometry to 
determine the percentage of remaining target cells that are either CFSE+ or CD45.1+.  White 
bar correspond to FBL-3 challenged and αCD8+αCD137 treated group, whereas grey bar 
correspond to the mice additionally treated with DT. Differences between the two groups 
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were analyzed by using t-test. Statistically significant differences between the groups are 
given in the figures (*P˂0.05). Experiment was repeated two times with comparable results. 
 
This killing activity of CD137-stimulated Foxp3+CD4+ T cells was confirmed in 
another in vivo cytotoxicity assay, in which we directly used FBL-3 tumor cells as 
targets (described in materials and methods). The FBL-3 cells were transferred into 
the peritoneal cavity of naïve mice together with donor Foxp3+CD4+ T cells from 
tumor challenged mice either left untreated, treated with αCD8 or αCD8+αCD137 
treated. Forty-eight hours later we re-isolated and quantified the remaining FBL-3 
cells by a peritoneal lavage. In mice that received Foxp3+CD4+ T cells from 
αCD8+αCD137 treated animals up to 90% of the tumor cells were eliminated (Fig. 
5.22). This FBL-3 cell killing was significantly higher than in groups that received 
Foxp3+ cells either from non-treated or only αCD8 treated mice tumor-bearing mice 
(Fig. 5.22). Thus, responding to αCD137 therapy a subset of Tregs obtained an 
effector phenotype of cytotoxic CD4+ T cell and was able to eliminate FBL-3 tumor 
cells in vivo. 
 
Figure 5.22: Tregs eliminate FBL-3 tumor cells following αCD137 therapy 
Mean percentages of killing are presented. Naïve CD45.1 mice received i.p. injection of FBL-
3 cells labeled with CFSE. Additionally, mice received sorted CD4+GFP+ cells from either 
αCD8, or αCD8+αCD137 tumor-bearing or naïve mice.  Mice were sacrificed 48 hrs later and 
intraperitoneal lavage was performed. The results depict mean percentages of FBL-3 cells 
killing calculated according to control, only FBL-3 challenged mice. Each dot represents an 
individual mouse. Differences between the two groups were analyzed by using one-way 
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ANOVA test. Statistically significant differences between the groups are given in the figures 
(*P˂0.05). Experiment was repeated two times with comparable results. 
 
5.9 αCD137 treatment does not convert conventional CD4+ T cells into 
Foxp3+ CD4+ T cells 
The appearance of Foxp3+CD4+ T cells with cytotoxic activity against tumor cells 
after αCD137 therapy might be explained by two different pathways. The Tregs 
convert into cytotoxic effectors or conventional CD4+ T cells with cytotoxic potential 
may start to express Foxp3 after CD137 signaling. To test these possibilities, an 
adoptive transfer experiment with Foxp3+ or Foxp3- donor cells (CD45.2+ cells were 
from DEREG mice and distinguished based on their GFP expression) into CD45.1 
mice that were challenged with FBL-3 cells and treated with αCD8 and αCD137 
antibodies. After 6 days the donor cells were re-isolated from the tumor-drLNs and 
analyzed for their Foxp3 and Eomes expression. None of the conventional CD4+ T 
cells (Foxp3- donor cells) that expressed Eomes also expressed Foxp3. However, 
14% of the transferred Tregs (Foxp3+ donor cells) started to additionally express 
Eomes in the recipient mice (Fig. 5.23), supporting our previous results that Tregs 
can be reprogrammed into Eomes+ effector T cells after CD137 signaling (Fig. 5.17 
and 5.18). In contrast, no induction of Foxp3 expression in conventional cytotoxic 
CD4+ T cells was observed after antibody treatment (Fig. 5.23). 
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Figure 5.23: Influence of αCD137 treatment on the phenotypic stability of 
Foxp3+CD4+ T cells 
CD45.1 mice were challenged with FBl-3 cells and additionally transferred i.v. with sorted 
CD4+GFP- or CD4+GFP+ cells from naïve DEREG mice and treated with αCD8+αCD137 as 
described in methods. Six days after tumor challenged intracellular expression of Foxp3 and 
Eomes on transferred CD45.1-CD45.2+ cells was detected. Data are representative for 3 
independent experiments. 
 
5.10 Role of CD137 treated Foxp3+ CD4+ T cells in FBL-3 tumor formation 
Next, it was of interest to investigate the direct influence of converted Tregs during 
FBL-3 tumor formation in vivo. In order to demonstrate that, we studied tumor 
regression in mice which either lack Foxp3+ T cells (DT-treated) while treated with 
αCD8+αCD137 or additionally challenged with Foxp3+ T cells (GFP+-sorted) from 
αCD137 treated mice. Interestingly, after a selective depletion of Foxp3+ T cells in 
tumor-bearing DEREG αCD8+αCD137 therapy did not significantly improve tumor 
elimination. In contrast, αCD8+αCD137 treated mice could eliminate FBL-3 tumor 4 
days earlier in comparison to those that additionally were depleted for Foxp3+ T cells 
(Fig. 5.24). However, these results do not indicate the contribution of converted CD4+ 
Foxp3+ T cells to tumor elimination, since DT injection depleted both populations of 
converted CD4+ Foxp3+ T cells and suppressive Tregs. The latter in turn results in 
effector CD4+ T cell activation and subsequent FBL-3 tumor elimination (2). 
GFP
GFP-
0%
CD45.1
+FBL-3
+αCD8
+αCD137
CD4
Eomes
F
o
x
p
3
GFP+
F
o
x
p
3
Eomes
14%
DEREG CD45.2 naïve
6%
RESULTS 
75 
 
Figure 5.24: Influence of CD8 depletion and αCD137+DT therapy on tumor 
formation 
DEREG mice were injected s.c. with 1×107 FBL-3 cells and tumor size was measured. Mice 
were depleted for CD8+ T cells and treated with αCD137 and DT as described in methods. 
Lines represent means of tumor progression in 5-7 mice. 
 
To clarify the pure effect of the converted CD4+ Foxp3+ T cells, we used nude 
(Foxn1nu) mice that have deteriorated or absent thymus and therefore no T cells. 
These mice received GFP+Foxp3+ T cells from DEREG tumor-bearing mice either 
treated or non-treated with αCD8+αCD137 following FBL-3 tumor challenge one day 
later. None of the groups could control tumor growth (Fig. 5.25). However, an 
injection of Foxp3+ T cells from αCD8+αCD137 into tumor-challenged nude mice 
caused the decrease in size of FBL-3 tumor and up for 6 days prolonged the survival 
of these mice in comparison to control groups (Fig. 5.25). Collectively, these data 
suggest that following CD137 stimulation Foxp3+ T cells can contribute to effector 
anti-tumor immune response and delay tumor progression. 
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Figure 5.25: Influence of different Treg populations on tumor formation in nude 
mice 
Nude mice (Foxn1nu) were injected s.c. with 1×106 FBL-3 cells and tumor size was 
measured. One day before tumor injection some group of mice received GFP+ Foxp3+ T cells 
from DEREG mice either treated with αCD137+αCD8 (red line) or not-treated (blue line). The 
black line represents tumor growth in nude mice challenged with FBL-3 cells only. Lines 
represent means of tumor progression in 2 mice. Dragger symbol: mice were euthanized due 
to progressive tumor growth. 
 
5.11 αCD137 treatment also leads to the activation of Foxp3+ effector 
CD4+ T cells in the presence of CD8+ T cells 
It has been shown before that cytotoxic CD8+ T cells are critical in FBL-3 tumor 
control (64, 133). In cancer patients CD8+ T cells are often exhausted and failed to 
prevent tumor cell dissemination (159). An administration of CD137 costimulatory 
antibody into tumor challenge mice with existing CD8+ T cells may not only restore 
the function of exhausted CD8+ T cells but could also influence effector CD4+ T cells 
including Foxp3+CD4+ T cells. However, CD8+ T cells consume large amounts of 
CD137 ligands, which might prohibit the effect on CD4+ T cells. Therefore, it was of 
interest to investigate the influence of CD137 agonist antibody on the Foxp3+CD4+ T 
cell compartment in the presence of CD8+ T cells. Figure 26 demonstrates that in the 
presence of CD8+ T cells administration of agonist CD137 antibody into FBL-3 
challenged mice nonetheless resulted in a significant expansion of Foxp3+ T cells 
(Fig. 5.26A) that were highly activated (Fig. 5.26B) and possessed significant 
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proliferation capacity (Fig. 5.26C) compared to the naïve controls. Remarkably, there 
was no significant difference in the expansion, activation and proliferation levels of 
Foxp3+ T cells from CD8-depleted versus non-depleted mice after CD137 agonist 
treatment (Fig. 5.26B-C).  
 
Figure 5.26: αCD137 therapy leads to the activation of Foxp3+ T cells in the 
presence of CD8+ T cells 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and treated with αCD137+αCD8 or with 
αCD137 alone as described in methods. At day 6 ptc draining lymph nodes were analyzed 
for expression of different molecules by flow cytometry. A, total numbers of Foxp3+CD4+ T 
cells are shown. B, total numbers of surface expression of CD11a and CD43 (double 
positive). C, the proliferation of Foxp3+ T cells was measured by the intracellular expression 
of Ki67. Differences between the two groups were analyzed by using one-way ANOVA test. 
Statistically significant differences between the groups are given in the figures (*P˂0.05, n.s. 
– not significant). The experiment was performed two times. 
 
To study the induction of Foxp3+ CD4+ T cells with helper T cell phenotype after 
agonistic CD137 therapy we stained for CD154 and TNFa. Interestingly, a significant 
induction of CD4+ T cell that expressed Foxp3 and at the same time produced TNFα 
or expressed CD154 after CD137 antibody treatment was observed in the presence 
0
20000
40000
60000
N
u
m
b
e
rs
 o
f 
C
D
4
+
F
o
x
p
3
+
p
e
r 
m
il
li
o
n
 c
e
ll
s
Naïve CD137 CD8+CD137
*
*
0
5000
10000
15000
20000
25000
N
u
m
b
e
rs
 o
f
C
D
4
+
F
o
x
p
3
+
C
D
1
1
a
+
C
D
4
3
+
p
e
r 
m
il
li
o
n
 c
e
ll
s
Naïve CD137 CD8+CD137
n.s.
*
0
10000
20000
30000
40000
50000
N
u
m
b
e
rs
 o
f 
C
D
4
+
F
o
x
p
3
+
K
i6
7
+
p
e
r 
m
il
li
o
n
 c
e
ll
s
Naïve CD137 CD8+CD137
n.s.
*
A B
C
CD4+Foxp3+ CD11a+CD43+
Ki67+
RESULTS 
78 
of CD8+ T cells, although the size of this effector CD4+ T cell populations were 
smaller than in additionally CD8-depleted mice (Fig. 5.27A-B).  
 
 
Figure 5.27: Tregs acquire a helper T cell-like phenotypes after αCD137 
treatment in the presence of CD8+ T cells 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and treated with αCD137+αCD8 or with 
αCD137 alone as described in methods. At day 6 ptc Foxp3+ Treg cells from draining lymph 
nodes were analyzed for different characteristics. A, numbers of Foxp3+ T cells expressing 
CD154 molecule. C, CD154+Foxp3+ T cells producing TNF-α. Differences between the two 
groups were analyzed by using one-way ANOVA test. Statistically significant differences 
between the groups are given in the figures (*P˂0.05, **P˂0.005, ***P˂0.0005). The 
experiment was performed one time (four mice per group). 
 
The cytotoxic characteristics of Foxp3+ T cells following αCD137 therapy in the 
presence of CD8+ T cells were also analyzed. Again, expression of the transcription 
factor Eomes and the cytotoxic molecule granzyme B was significantly enhanced in 
Foxp3+ T cells from tumor-bearing mice treated with αCD137 even in the presence of 
CD8+ T cells compared to naïve mice (Fig. 5.28A and 5.28B). A representative dot 
plot in figure 5.28B of conCD4+ and Foxp3+ T cells shows the increased granzyme B 
production after αCD137 therapy. Only for granzyme B but not for Eomes the 
population of cells expressing these molecules was significantly bigger after 
additional depletion of CD8+ T cells. Collectively, these data suggest that even in the 
presence of CD8+ T cells agonist CD137 costimulatory therapy can convert 
Foxp3+CD4+ Tregs into effector cells with a cytotoxic phenotypes. 
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Figure 5.28: Tregs acquire effector-like phenotype following αCD137 therapy in 
the presence of CD8+ T cells 
B6 mice were inoculated s.c. with 1×107 FBL-3 cells and treated as described in methods. At 
day 6 ptc Foxp3+ Tregs from draining lymph nodes were analyzed for transcription factor 
Eomes (A) and production of GzmB (B). C, representative dot plots of Eomes+Foxp3+ Tregs 
in different treatment of mice are shown. Differences between the two groups were analyzed 
by using one-way ANOVA test. Statistically significant differences between the groups are 
given in the figures (*P˂0.05, ***P˂0.0005, n.s. – not significant). The experiment was 
performed one time (four mice per group). 
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6 DISCUSSION 
Cell-mediated immunity plays an important role in immune responses against cancer. 
The CD4+ T cell immune response represents a critical part of a functional immune 
system and is well characterized in many tumor diseases but its role in immunity 
against oncogenic viruses remains unclear. Over the last years the idea that Tregs, a 
subset of CD4+ T cells, can undergo functional plasticity has received growing 
attention. In the current study, we have used the highly immunogenic FV-induced 
FBL-3 tumor cell line as a model to study the mechanisms of immunological tumor 
control by CD4+ T cells and Tregs. In a previous study, we reported that in this FBL-3 
tumor model Tregs suppress effective anti-tumor CD4+ T cell immune responses and 
thereby contributed towards tumor progression (2). Cytotoxic CD4+ T cells could fully 
compensate for the anti-tumor effect of CD8+ T cells, when their suppression by 
Tregs was abrogated due to Treg depletion. In the current work we show that 
administration of an agonist antibody against CD137, an activation induced 
costimulatory molecule, into mice lacking CD8+ T cells promoted effective cytotoxic 
anti-tumor CD4+ T cell immune responses and led to FBL-3 tumor elimination in the 
presence of Tregs. Interestingly, αCD137 therapy converted a subpopulation of 
Foxp3+ Tregs into tumor cell killing effector CD4+ T cells. Our results reveal a unique 
population of Foxp3+CD4+ T cells adopting the anti-tumor effector functions of 
conventional CD4+ T cells upon CD137 signaling.  
The TNFR family members which have been found to play major roles as co-
stimulatory receptors for CD4+ and CD8+ T cells are CD134, CD137, CD27, CD357, 
CD30, CD270, DR3, CD267, and CD120b. Targeting these receptors expressed by 
immune cells is a promising approach for treating patients with cancer. When these 
receptors are ligated either by their cognate or by agonist antibody, a wide variety of 
cellular outcomes have been reported ranging from cell differentiation, proliferation, 
apoptosis and survival to increased production of cytokines and chemokines (36, 40, 
42, 45, 98). The first of the TNFR family members to be identified as a possible 
immunotherapy target was CD137 (92). The efficacy of its ligation was shown in 
different tumor studies as well as viral infections, demonstrating that treatment of 
tumor-bearing mice with CD137 agonist therapy promoted effective anti-tumor and 
anti-viral immune responses. Another costimulatory member of the TNFR family is 
CD134 that has stimulatory effects on all T helper cell lineages (151), including 
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increased cytokine production. Interestingly, a combination of CD137 and CD134 
treatment drives cytotoxic CD4+ T cell differentiation which in turn results in effective 
tumoricidal immune functions in a mouse melanoma model (109). In the study 
presented here, the usage of CD137 agonist therapy alone was sufficient to control 
FBL-3 tumor formation even in the absence of CD8+ T cells.  
Since the use of αCD137 agonist antibody as an anticancer immunotherapy was first 
proposed, it has been assayed in a number of different tumor model systems (84). 
CD137 expression is more prominent on CD8+ T cells than on CD4+ T cells and 
therefore most tumor immunotherapy studies have been focused on the impact of 
αCD137 on CD8+ T cells (122). In the murine tumor model of sarcoma and 
mastocytoma, administration of immune co-stimulatory anti-CD137 has been found to 
significantly decrease the tumor size (92). This effect was highly dependent on CD8+ 
as well as on CD4+ T cells, since agonist CD137 therapy failed to suppress tumor 
growth in mice deficient for CD4+ and/or CD8+ T cells (72, 146). In a murine model of 
breast cancer, treatment with αCD137 resulted in the CD8+ T cell-mediated 
regression of pre-established tumors and a survival rate of 87% (88). In our tumor 
model both CD4+ and CD8+ T cell alone could control the growth of FBL-3 cells when 
stimulated with αCD137. However, depletion of all T cells (CD8+ and CD4+ T cells) 
during αCD137 treatment resulted in progressive tumor growth (Fig. 5.1D). The 
results clearly demonstrate the anti-tumor effector function of CD4+ T cells when 
stimulated with CD137 antibody (Fig. 5.1D). In many tumor entities and tumor models 
tumor specific CD8+ T cells are functionally impaired or dysfunctional, which likely 
contributes to the often observed limited efficacy of immunotherapy (159). Previously, 
we showed that tumor specific CD4+ T cells apart from being helper cells can 
substitute for the function of CD8+ T cells and efficiently control tumor growth (2). A 
targeted activation of tumor-specific CD4+ T cells by co-stimulatory CD137 antibody 
might therefore substantially contribute to anti-tumor immunity and immune control of 
tumor progression. 
It has already been shown that there are many effector mechanisms by which CD4+ 
T cells can combat tumor cells: cytotoxins (granzymes and the pore forming protein 
perforin), cytokines (IFN-γ, TNF-α, IL-2) and membrane-associated death proteins 
(FasL signaling) (49, 107, 111, 117, 123). In the current study, we investigated 
whether CD4+ T cells in drLN expressed pro-inflammatory cytokines (IFN-γ, TNF-α, 
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and IL-2), as well as granzyme B in response to FBL-3 challenge following CD137 
co-stimulatory treatment. 
CD4+ T cells are characterized by their ability to produce cytokines, and play a critical 
role in the anti-tumor immunity (71). For example, the effective immune response to 
HPV which controls the development of benign lesions, is mediated by CD4+ T cells 
producing cytokines (126). In the FV mouse model IFN-γ production by CD4+ T cells 
is an important component in the infection control (100). One major form of T cell 
help comes from the transient expression of CD154 (CD40L) on activated CD4+ T 
cells, which interacts with CD40 on the surface of dendritic cells (DCs), enhancing 
their expression of both MHC and co-stimulatory molecules, as well as by stimulating 
the production of cytokines (e.g. IL-2) (116, 132). In both anti-cancer and anti-viral 
therapies, agonist CD137 therapy expands effector cells that can produce high levels 
of cytokines, such as IFN-γ, TNF-α and IL-2 (93, 99, 155). Studies using cytokine and 
cytokine receptor knockout mice have also provided additional information. For 
instance, mice that were deficient in their ability to produce IFN-γ failed to develop 
effector anti-tumor immune responses even after administration of αCD137 antibody. 
Here we show that CD137 agonist therapy resulted in significantly increased 
numbers of CD4+ T cells producing the pro-inflammatory cytokines, IFN-γ, TNF-α and 
IL-2 (Fig. 5.6). Not unexpectedly, the cytokine producing CD4+ T cells in tumor drLNs 
were CD154 positive cells. This observation indicates that these CD4+ T cells were 
activated by tumor antigen and became tumor specific cells that contributed to FBL-3 
tumor control. Interestingly, studies performed by using a blocking CD154-specific 
antibody inhibited the formation of effective anti-tumor immune responses that was 
not overcome by CD137-mediated signals (93). In contrast, blocking CD137 
expression was associated with downregulation of IFN-γ and TNF-α in CD8+ T cells 
and NK cells in chronic obstructive pulmonary disease (57). 
Here, we show that the anti-tumor CD4+ T response in the absence of CD8+ T cells 
was altered by αCD137 immunotherapy. This alteration resulted in an increased 
expression of activation molecules, such as CD11a, CD43 and a higher proliferation 
capacity. Moreover, KLRG-1, a cadherin receptor that is associated with terminal 
differentiation and senescence in T cells (56), was significantly increased on CD4+ T 
cells after CD137 ligation (Fig. 5.3). Recently, it has been demonstrated that in B16 
melanoma KLRG-1+ tumor-infiltrating CD4+ T cells play an important role in response 
to immunotherapy with a Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) blockade and 
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CD137 agonist antibody (27). The authors showed that CD137 agonist antibody 
treatment induced a widespread expression of KLRG-1 on both CD8+ and CD4+ 
effector T cells that correlated with positive therapeutic outcome. We show here that 
expansion of highly activated and differentiated CD4+ T cells corresponded with the 
tumor-specific CD4+ T cells expansion and tumor control after CD137 agonist 
antibody therapy (Fig. 5.4).  
Tumor-specific CD4+ T cells can mediate killing of established tumors as 
demonstrated by the tumor-specific CD4+ T cells used in the B16 melanoma model 
(108). The dominant cytotoxic mechanism utilized by effector CD4+ T cells is the 
induction of apoptosis by the direct release of cytotoxic granules into a target cell. 
Contained within these granules are granzymes that gain intracellular access into 
target cells with the help of the protein perforin, which polymerizes to form channel 
pores through the plasma membrane (described in Introduction). Granzyme/perforin-
mediated cytolytic activity has been suggested for virus-specific CD4+ T cells that 
recognized peptides derived from EBV latent membrane proteins (50), HIV-1 gag 
protein (103) or poliovirus (142). Perforin-deficient mice are more susceptible to 
spontaneous lymphomas (124), suggesting that the perforin-granzyme pathway plays 
a role the in immune surveillance of several types of cancers. It has become 
apparent that the cytotoxic potential of tumor-specific CD4+ killer T cells depends on 
the expression of the transcription factor Eomes (28). Additionally, it was 
demonstrated that Eomes plays an important role in initiating granzyme production in 
T cells (109). In agreement with this study, we show here that an increased level of 
granzyme B following αCD137 therapy correlates with levels of Eomes expression in 
the CD4+ T cell compartment (Fig. 5.7). The study by Qui et.al. also described in vitro 
differentiation of naïve CD4+ T cells into cytotoxic T-helper cells, in which Eomes, 
similar to CD8+ T cells, initiates the cytotoxic function (109). However, in this study 
immunotherapy with two agonists of co-stimulatory molecules, αCD137 plus αCD134, 
was used. In the current study αCD137 therapy alone was able to initiate cytotoxic 
CD4+ T cell function and expansion of CD4+ T cells expressing Eomes (Fig. 5.7). 
Thus, CD137 signaling can obviously initiate a transcriptional program in CD4+ T 
cells that results in potent cytotoxic activity of these cells.  
In order to demonstrate that the increased expression of granzyme B by effector 
CD4+ T cells resulted in tumor specific lysis of target cells after CD137 co-stimulatory 
therapy, we performed an in vivo CTL assay. CD4+ T cells showed potent killing 
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activity of peptide-loaded targets in the drLN of FBL-3-bearing mice (Fig. 5.9). The 
acquisition of cytotoxic activity by tumor-reactive CD4+ T cells emerged when the co-
stimulatory treatment was performed. Cytotoxic CD4+ T cells targeting viral antigens 
(54, 55, 104) and alloantigens (58, 108, 125) have been described previously, but in 
these models the effector CD4+ T cell activity was not regulated by co-stimulation 
and the pathogen was eliminated either by adoptive transfer of effector CD4+ T cells 
(62, 108) or by improved CD4+ T cell recognition (54). Quezada et al. (108) showed 
effector CD4+ T cell dependent tumor rejection when radiotherapy and adoptive 
transfer of tumor-reactive CD4+ T cells were combined with the blockade of CTLA-4, 
a protein receptor that is involved in downregulating the immune system (114). We 
now report that targeting a costimulatory pathway alone resulted in maintaining 
immune control over the FBL-3 tumor via direct killing by effector CD4+ T cells.  
It is of significance to the current discussion, that it has been recognized that in 
addition to being expressed on activating effector T cells, many TNFR family 
members, including CD137 are constitutively expressed on CD4+Foxp3+ Tregs (20, 
91) (Fig. 5.11). Until now it has been unclear whether agonist CD137 antibody 
treatment exerts pro- or anti-suppressive effect on Tregs (20, 33, 73, 156). The 
engagement of CD137 on Tregs can increase their number (33, 156), and the 
stimulation of Tregs with a CD137-Fc fusion protein expands Tregs without changing 
their function (156). In contrast, another study showed that CD137 ligation on Tregs 
with an agonist antibody suppressed their function in vitro without inducing 
proliferation (20). The differences in these studies, although unsolved, might reflect 
alterations in the signal strength or in other aspects of the stimulation conditions. In 
the current work mice lacking CD8+ T cells and challenged with tumor showed a 
significant expansion of Foxp3+ Tregs comprising up to 30% of all CD4+ T cells in the 
tumor-drLNs after αCD137 treatment (Fig. 5.12A). Additionally, the Tregs found 
following αCD137 therapy in vivo were highly activated, differentiated, and had high 
proliferation capacity. (Fig. 5.13 and 5.14). This clearly demonstrates that αCD137 
indeed induces signaling in Tregs. 
Tregs can be divided into the two groups of natural occurring thymus-derived Tregs 
(nTreg), and peripherally induced Tregs (iTreg) that can develop from conventional T 
cells (26). It has recently been reported that nTregs express Neuropilin-1 while iTregs 
do not (152). The analysis of the expanded Treg subset showed that the vast 
majority of Tregs expanding after αCD137 treatment in FBL-3-bearing mice 
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expressed Neuropilin-1 (Fig. 5.15), suggesting that those cells were mostly thymic-
derived nTregs.  
It is well known that Tregs suppress beneficial immune responses against pathogens 
and limiting antitumor immunity (139). Dietze et al. showed that exhausted CD8+ T 
cells were reactivated and reduced viral loads after depletion of Tregs during chronic 
FV infection (29). During acute FV infection Treg depletion in DEREG mice augments 
cytotoxicity of virus-specific CD4+ T cells (86). Iwashiro et al. demonstrated that mice 
persistently infected with FV approximately doubled the normal percentage of splenic 
CD4+CD25+ Tregs and lose their ability to reject the implantation of FBL-3 cells (64). 
We have previously demonstrated that direct anti-tumor effects of CD4+ T cells in 
FBL-3 tumor model were limited by Tregs (2). When CD8+ T cells were absent, Tregs 
suppressed effector CD4+ T cell responses and promoted tumor growth (Fig. 5.10) 
(2). Therefore, under most circumstances the role of Tregs is clearly 
immunosuppressive. In regards to our study, the αCD137 therapy overruled this Treg 
suppression and enabled effector CD4+ T cell control of FBL-3 tumor growth, 
suggesting that CD137 signaling may influence Treg functions. One possible 
pathway is that Foxp3 expressing Tregs retain a certain degree of plasticity and 
under specific conditions they may adopt a pro-inflammatory phenotype (77). This 
phenotype includes a “helper-like” role and has been observed in different models, 
including vaccination (137), tumors (1) and graft rejection (140). In particular, Addey 
et al. (1) showed that in the murine urothelial carcinoma model Tregs can upregulate 
genes characteristic for a T helper cell phenotype, such as pro-inflammatory 
cytokines. Remarkably, in the current work CD137 agonist therapy induced 
expression of markers characteristic for T helper cells (CD154) or cytotoxic T cells 
(Eomes) in CD4+ Foxp3+ cells. We show here that upon αCD137 therapy CD154 was 
expressed on a subset of Foxp3+CD4+ T cells. Moreover, the CD154+Foxp3+ CD4+ T 
cell subset expressed the pro-inflammatory cytokine TNF-α, supporting the functional 
plasticity of the Foxp3+CD4+ T cells. It has been shown that in drLNs of vaccinated 
mice Tregs can undergo reprogramming and upregulate CD154 (118), which goes in 
line with our studies. Interestingly, Sharma et al. (118) advanced that Tregs 
reprogrammed in response to inflammatory stimuli are specifically needed to provide 
help in the early cross-priming of CD8+ T cells, leading to effective tumor immunity. 
Of note, in this work, the function of reprogrammed Tregs depended on the loss of 
Foxp3 expression, which contradicts the studies suggesting that once established 
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Foxp3 expression is highly stable in Tregs (95). In contrast, we report that 
functionally reprogrammed Tregs upon CD137 agonist therapy maintained Foxp3 
expression. In a recent study by Sharma et al. (119) it has also been demonstrated 
that in response to specific inflammatory signals Foxp3+CD4+ T cells transformed into 
biologically important helper cells, without loss of Foxp3 expression. Interestingly, in 
vitro restimulation in the presence of transforming growth factor β (TGF- β) induced a 
major subset of Tregs to reacquire Foxp3 expression, whereas Tregs without TGF- β 
retained an effector phenotype and produced pro-inflammatory cytokines (74), 
indicating that mechanisms controlling Foxp3 stability are reversible and may allow 
adaption to changing microenvironments. 
Importantly, Tregs plasticity can contribute to several human diseases. IPEX patients 
have an increased frequency of IL-17-producing cells that is thought to be sustained 
by inflammatory driven conversion of Tregs that develop in the thymus (106). 
Similarly, Foxp3+IL-17+ cells were also recognized in patients with allergic rhinitis and 
polyposis (81) and in the intestinal mucosa of Crohn’s disease patients (59). Another 
study by Kryczek et al. identified a population of Foxp3+IL-17+ cells that accumulate 
in the patients with colon carcinoma as well as in ulcerative colitis (76). These cells 
originated from memory T cells or Tregs and displayed both an inflammatory and 
regulatory phenotype. There is also sufficient evidence to suggest that Tregs can be 
reprogrammed towards a Th1 phenotype as Foxp3+IFN-γ+ cells were found to be 
increased in type 1 diabetes patients compared to healthy controls (89). However, it 
has not been addressed so far whether Foxp3+CD4+ T cells can undergo conversion 
that will change their functional capability and turn them into cytotoxic CD4+ T cells. 
In the current study we describe for the first time a subpopulation of CD4+Foxp3+ T 
cells that expresses the cytotoxic transcription factor Eomes while maintaining 
Foxp3+ Treg identity after αCD137 treatment. These cells constituted up to 15% of all 
Foxp3+ T cells (Fig. 5.18). The conversion of Treg cells into cytotoxic Eomes+CD4+ T 
cells was accompanied by granzyme B production (Fig. 5.19). Moreover, these 
reprogrammed Foxp3+Eomes+ CD4+ T cells contributed to FBL-3 tumor clearance 
(Fig. 5.21). It has been recently shown that granzyme B producing Tregs can kill 
tumor cell targets (19). However, these cells were redirected by bispecific antibodies, 
and classical TCR involvement in specific tumor cell recognition was absent. 
Although we presume that the granzyme pathway is used in the FBL-3 model by 
Foxp3+CD4+ T cells to kill tumor cells, there are still unanswered questions regarding 
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this pathway in Foxp3+-mediated killing. Because granzyme B appears to be an 
induced molecule in Tregs, it is also important to determine what signaling factors, 
apart from improved co-stimulatory conditions, are required to activate this pathway.  
It was of interest to establish the origin of Foxp3+ CD4+ T cells coexpressing the 
cytotoxic transcription factor Eomes, and thus provide formal proof of the plasticity of 
those cells. To this end, an adoptive transfer experiment was performed with DEREG 
mice, expressing GFP under the Foxp3 promoter to measure conversion of Foxp3- to 
Foxp3+ cells following αCD137 therapy. Our results showed that no conversion of 
conventional CD4+ T cells to Foxp3+ cell was observed but already Foxp3+ T cells 
started to co-express Eomes after αCD137 treatment (Fig. 5.23). However, it is still 
unclear, whether cells that coexpress Foxp3 and Eomes represent an intermediate, 
transitional stage of reprogrammed Tregs that retain the potential to engage in 
reprogramming or revert to their maternal origin. Moreover, it is also unclear if Foxp3+ 
cells are cytolytic and suppressive at the same time. This is very important as it might 
influence the course of disease and choices of immunotherapy. 
Additional studies will be required to clarify the antigen specificity of the 
reprogrammed Foxp3+ CD4+ T cells. In general, the Foxp3+CD4+ T cell population is 
thought to include many TCRs that recognize self peptides (38). It has been 
hypothesized that this recognition allows reprogrammed Foxp3+ CD4+ T cells to 
interact spontaneously with APCs without cognate specificity for the new antigen 
(118). 
In conclusion, our studies have established critical role for effector CD4+ T cells and 
effector Foxp3+ T cells in the control of oncoviral diseases. When CD8+ T cells were 
dysfunctional and unable to control FBL-3 tumor development, effector CD4+ T cells 
were able to attack and abolish the tumor following CD137 agonist therapy, 
suggesting a direct anti-tumor capacity for those cells. In the current work we provide 
evidence that CD137 stimulation can induce granzyme B production in Tregs and 
converts these cells into Foxp3+ cytotoxic killer cells that contribute towards antigen-
specific tumor rejection in vivo. The findings presented here may have implications 
for vaccination against tumors that escape immunosurveillance to establish cancer. 
We suggest that a cytotoxic CD4+Foxp3+ T cell response may be induced by co-
stimulatory signals to enhance resistance against virus-associated tumors. Finally, 
our results should encourage researchers to develop new reagents to manipulate 
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Tregs and CD4+ T cells in vivo that may be used for immunotherapy of malignancies 
caused by oncoviruses. 
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7 SUMMARY 
Recent successes in immune therapeutic strategies aimed to improve control over 
tumor growth have sparked the hope that long-lived control of cancer through 
stimulation of the immune system can be possible. However, the underlying 
immunological mechanisms that are induced by immunotherapeutic strategies are 
not well understood. Here, we used the highly immunogenic FV-induced FBL-3 tumor 
as a model to study the mechanisms of immunological tumor control by CD4+ T cells 
in the course of CD137 (4-1BB) agonist immunotherapy and in the absence of a 
visible CD8 T cell response. CD137 is a member of the Tumor Necrosis Factor 
Receptor (TNFR) superfamily, which is involved in T cell activation and function, 
including expansion, survival, and cytokine production of effector T cells. We 
demonstrate that treatment with a CD137 agonist resulted in complete FBL-3 tumor 
regression in CD8+ T cell deficient mice. CD137 signaling enhanced the production of 
pro-inflammatory cytokines, such as IFN-γ, TNF-α, and IL-2, and cytotoxic molecule 
granzyme B in tumor-specific CD4+ T cells. Over the last years the idea that Tregs, a 
suppressive subset of CD4+ T cells, can undergo functional plasticity has received 
growing attention. Interestingly, in addition to being expressed on activating effector 
T cells the CD137 molecule is constitutively expressed on CD4+Foxp3+ Tregs. In the 
current study, we showed that the engagement of CD137 on Tregs resulted in 
expansion of their numbers and that they were mostly thymic-derived nTregs. 
Additionally, the Tregs found following αCD137 therapy in vivo were highly activated, 
differentiated, and had high proliferation capacity. Moreover, a subset of CD4+Foxp3+ 
Treg cells was reprogrammed to eliminate virus-induced tumor cells in response to 
CD137 agonist treatment. These converted Tregs expressed a marker characteristic 
for T helper cells (CD154) and produced the cytokine TNF-α or the cytotoxic 
transcriptional factor Eomesodermin (Eomes) and granzyme B without loss of Foxp3 
expression. Foxp3 Eomes double-positive CD4+ cells were capable of eliminating 
virus-induced tumor cells in vivo.  
Our results reveal a unique population of Foxp3+ CD4+ T cells adopting the anti-
tumor effector functions of conventional CD4+ T cells upon CD137 signaling. 
Therefore, this study might contribute to the development of new reagents to 
manipulate Tregs and CD4+ T cells in vivo that can be used for immunotherapy of 
malignancies caused by oncoviruses. 
ZUSAMMENFASSUNG 
90 
8 ZUSAMMENFASSUNG 
Jüngste Erfolge bei der immuntherapeutischen Behandlung von entarteten 
Krebszellen durch Stimulation bestimmter Immunzellen wecken die Hoffnung, das 
Tumorwachstums lebenslang kontrollieren zu können. Allerdings sind die 
immunologischen Mechanismen, die den immuntherapeutischen Strategien 
zugrundeliegen, bis heute nicht vollständig geklärt. 
In dieser Arbeit wurde die Kontrolle des Tumorwachstums durch CD4+ T-Zellen in 
Anwesenheit des CD137 (4-1BB)-Agonisten untersucht. Als Tumorzelllinie wurden 
die immunogenen, FV-induzierten FBL-3 Zellen verwendet, die stets in Abwesenheit 
von CD8+ T-Zellen untersucht wurden. CD137 ist ein Mitglied der 
Tumornekrosisfaktor-Rezeptor (TNFR) Superfamilie, welches bei der 
T-Zellaktivierung und T-Zellfunktion, wie z.B. Expansion, Überleben und 
Zytokinproduktion, mitwirkt. In dieser Arbeit konnten wir zeigen, dass die Behandlung 
mit dem CD137-Agonisten in CD8+ T-Zell-depletierten Mäusen zu einem 
vollständigen Rückgang des FBL-3 Tumorwachstums führte. Dabei zeigte sich, dass 
CD137 die Produktion von proinflammatorischen Zytokinen, wie IFN-γ, TNF-α und 
IL-2, und des zytotoxischen Moleküls Granzym B in Tumor-spezifischen CD4+ 
T-Zellen induziert. In den vergangenen Jahren rückten regulatorische T-Zellen 
(Tregs), welche eine supprimierende Population innerhalb der CD4+ T-Zellen 
darstellen, in den Fokus der Forschung, da diesen eine funktionelle Plastizität 
zugesprochen wird. Interessanterweise wird CD137 nicht nur auf aktivierten Effektor 
T-Zellen, sondern auch konstitutiv auf CD4+Foxp3+ Tregs exprimiert. Wir konnten 
zeigen, dass die Bindung von CD137 an Tregs zu einer Expansion dieser 
bestimmten Tregs führte, welche hauptsächlich dem Thymus entstammen und als 
natürliche Tregs bezeichnet werden. Nach in vivo anti-CD137-Therapie war zu 
erkennen, dass Tregs einen stark aktivierten und differenzierten Phänotyp aufwiesen 
und eine vermehrte Proliferation zeigten. Zusätzlich stellte sich heraus, dass eine 
Subpopulation der CD4+ Foxp3+ Tregs durch Applikation des CD137-Agonisten 
umprogrammiert werden konnte, sodass diese daraufhin Virus-infizierte Tumorzellen 
eliminieren konnte. Diese umfunktionierten Tregs exprimierten den für T-Helferzellen 
charakteristischen Marker (CD154). Zusätzlich produzierten sie das Zytokin TNF-α 
und waren positiv für Eomesodermin (Eomes) und Granzym B. Interessanterweise 
führte die Umprogrammierung dieser Tregs nicht zum Verlust der Foxp3-Expression. 
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Es zeigte sich in vivo, dass die doppelt positiven Foxp3+Eomes+ CD4+ T-Zellen virus-
induzierte Tumorzellen töten konnten. 
Unsere Ergebnisse zeigen, dass eine bestimmte Population der Foxp3+ CD4+ 
T-Zellen über den CD137-Signalweg zu anti-Tumor Effektorzellen umgewandelt 
werden konnte. Daher könnte diese Manipulation von Tregs und CD4+ T-Zellen in 
vivo zur Entwicklung von neuen Medikamenten beitragen, welche dann zur 
immuntherapeutischen Bekämpfung von onkoviralen Krankheiten verwendet werden 
können. 
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10 APPENDIX 
10.1 List of Abbreviations 
Abbreviations Full name 
°C Degree Celsius 
µl Microlitre 
ADCC Antibody dependent cell mediated cytotoxicity 
AF 700 Alexa Fluor 700  
AF488 Alexa flour 488 
AF647 Alexa flour 647 
AIDS Acquired Immune Deficiency Syndrome 
ALV Avian leukemia virus  
APC Antigen presenting cells 
APC Allophycocyanin 
APC-Cy7 APC-cyanine7 
ASV Avian sarcoma virus 
B7RP1 B7-Related protein 1 
BCL-6 B cell lymphoma 6 
BLV Bovine leukemia virus 
BSA Bovine Serum Albumin 
BV421 Brilliant violet 421 
BV605 Brilliant violet 605 
CAD Caspase-activated deoxyribonuclease 
cAMP Cyclic adenosine monophosphate 
CD Cluster of differentiation 
CFSE Carboxyfluorescein succinimidyl ester 
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CTL Cytotoxic T cells 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
DC Dendritic T cell 
depl Depletion 
DEREG Depletion of regulatory T cells 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
drLNs draining lymph nodes 
DT Diphtheria toxin 
DTR Diphtheria toxin receptor 
EBV Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid, 
eF650 eFlour650 
eF780 eflour780 
eFluor 450 eFluor 450 
Env Envelope protein 
Eomes Eomesodermin 
FACS Fluorescence Activated Cells Scanner (Flow cytometer) 
FASL FAS ligand 
FCS Fetal Calf Serum 
FeLV Feline leukemia virus 
FeSV Feline sarcoma virus 
Fig Figure 
FITC Fluorescein isothiocyanate 
F-MuLV Friend murine leukemia virus 
Foxp3 Forkhead box P3 
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FSC Forward scatter 
FV Friend Virus 
FVD Fixable viable dye 
g Gram 
Gag Group specific antigen 
GATA-3 Gata binding protein 3 
GFI-1 Growth Factor Independent-1 
GFP Green fluorescent protein 
Gzm Granzyme 
HBV Hepatitis B Virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
HPV Human papillomavirus 
hrs Hours 
HTLV Human T-cell leukemia virus 
HTLV-1 Human T-Cell Leukemia Virus-1 
i.p. Intraperitoneal 
i.v. Intravenous 
ICOS Inducable costimulator 
IDO Indoleamine 2,3-dioxygenase 
IFN-γ Interferon gamma 
Ig Immunoglobulin 
IL Interleukin 
IPEX Immunodysregulation, polyendocrinopathy and enteropathy, X-linked 
syndrome 
iTregs Induced Tregs 
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KLRG-1 Killer cell lectin-like receptor subfamily G member 1 
KS Kaposi’s sarcoma 
KSHV Kaposi sarcoma-associated herpesvirus 
L Liter 
LAG-3 Lymphocyte-activation gene 3 
LNs Lymph nodes 
LTR Long Terminal Repeat 
Mab Monoclonal antibody 
mg Milligram 
MHC Major histocompatibility complex 
ml Millilitre 
mRNA messenger RNA 
MSV Murine sarcoma virus 
n.s. Non-significant 
NK Natural Killer cells 
Nrp-1 Neuropilin-1 
nTregs Natural Tregs 
PAMPs Pathogen-Associated Molecular Patterns 
PBBS Phosphate Buffered Saline, containing 1.0 g glucose 
PBS Phosphate Buffered Saline 
PD-1 programmed cell death 1 
PD-L1 programmed cell death ligand 1 
PE Phycoerythrin 
PE Cy5 PE-cyanine5 
PE Cy7 Phycoerythrin–Cy7 
PerCP Peridinin-chlorophyll-protein complex  
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PI Propidium iodide 
PMT Photomultiplier tube 
Pol Polymerase 
PRR Pathogen Recognition Receptors 
ptc post tumor challenge 
RNA Ribonucleic acid 
RORγt Retinoic acid receptor-related orphan receptor-γt 
RPMI-1640 Roswell Park Memorial Institute Medium 1640 
RSV Rous sarcoma virus 
s.c. Subcutaneous 
SFFV Spleen focus forming virus 
SPF Specific pathogen-free 
SSC Sideward scatter 
STAT Signal Transducer and Activator of Transcription 
Tcon Conventional CD4+ T cells 
TCR T-cell receptor 
Tetr Tetramer 
TetrII Tetramer Class II 
TGF-β Transforming Growth Factor-beta 
Th T helper cells 
TLR Toll-Like Receptor 
TNFR Tumor necrosis factor receptor 
TNF-α Tumor necrosis factor-alpha 
TRAIL Tumor-necrosis-factor-related apoptosis-inducing ligand 
TRAILR Tumor-necrosis-factor-related apoptosis-inducing ligand receptor 
Tregs Regulatory T cells 
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